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ABSTRACT
THE EFFECTS OF COCAINE AND ECSTASY ON CARDIAC MYOCYTES AND
THE INTACT MYOCARDIUM
David A. Tiangco
Old Dominion University, 2010
Director: Dr. Barbara Y. Hargrave

Cocaine and ecstasy are widely used illicit drugs. Both drugs have undergone
intense scrutiny as information regarding their side-effects has become available. One
important yet incomplete area of investigation pertains to their effects on the heart. The
purpose of the current studies was to test the hypothesis that exposure to cocaine or
ecstasy will adversely affect cellular homeostasis and normal heart function. Cultured
cardiac myocytes (H9c2) and New Zealand White rabbits (Oryctolagus cuniculus) were
used to measure the responses to various concentrations of cocaine or ecstasy at both the
cellular and intact organ system levels. We observed that cocaine and ecstasy
significantly altered several homeostatic parameters including reactive oxygen species
generation, intracellular calcium balance, N F - K B activity, gene expression, and left
ventricular function. We conclude that cocaine and ecstasy are detrimental to the
myocardium of the heart, causing several disturbances with pathological potential.
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INTRODUCTION

COCAINE

Background
Cocaine (benzoylmethylecgonine) is a naturally occurring alkaloid isolated from
the leaves of Erythroxylon coca, a South American shrub.1 This drug has a long history
and high frequency of abuse. A hair analysis study of a random adult population at a
major university in the United States revealed a 6% use/exposure rate.2 A recent
government estimate places the use of cocaine among United States teens at
approximately 4.8%, making it second only to marijuana in illicit drug use.3 Cocaine is
highly addictive and often taken for its euphoric and stimulatory properties. However,
this drug also has many unwanted side-effects, including some that adversely affect the
cardiovascular system.
Cocaine was the first local anesthetic agent in clinical use, and it was often
prescribed for ophthalmic and dental procedures.1,4 The anesthetic property of
cocaine relates to its ability to bind voltage-gated sodium channels and stabilize the
inactive conformation, thereby blocking trans-membrane conduction and intercellular
signaling in excitable tissues.5'6 In the heart, this effect may impair conduction velocity
through the myocardium or impede it altogether, thereby causing an arrhythmia or
cardiac arrest. In addition, cocaine has several sympathomimetic properties including the
ability to potentiate the release of epinephrine and norepinephrine from the adrenal
medulla.7 This may cause excess catecholaminergic stimulation to the heart and blood
The model for this thesis is Circulation.
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vessels, leading to increased heart rate, contractility, myocardial wall stress, and
vasoconstriction. Elevated circulating catecholamines may also lead to activation of the
renin-angiotensin system which causes an increase in the vasoconstrictor angiotensin II,
further raising blood pressure and increasing the afterload on the heart. Cocaine also
blocks the reuptake of norepinephrine and dopamine by binding to specific transport
proteins at pre-synaptic terminals and inhibiting their function.1'8'9 This effect potentiates
the actions of epinephrine and norepinephrine at post-synaptic sites such as the
myocardium and blood vessel walls. Cocaine is currently registered as a schedule II
compound with the Drug Enforcement Agency (DEA) of the United States in
recognition of its high abuse potential and limited medical use.
Toxicodynamics
Cocaine can be ingested or injected, however it is mostly internalized across oral,
nasal, or respiratory mucosal membranes via snorting or smoking. Two major forms of
the drug exist: the hydrochloride salt which is often snorted and the highly concentrated
free base known as "crack" which often smoked.10 A common recreational dose is
approximately 175 mg.11 However, the total amount can vary widely since frequent selfadministration within a short time period is typical for an addict with unfettered access
to the drug.11
In a study involving healthy human volunteers, a single intranasal dose of
1.5 mg/kg cocaine gave rise to peak plasma concentrations ranging from 120 to
474 ng/ml at approximately 15 to 60 min after administration.12 In another study, healthy
human volunteers were given a 175 mg dose of cocaine at the beginning of every hour
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over a 4 h time period.11 With this treatment, a dose dependent increase in plasma
concentration of cocaine was observed with peak levels ranging from 625 to
738 ng/ml at approximately 4.5 h after the first administration.
Plasma half-life for cocaine ranges from 45 to 90 min.13 The major route of
elimination involves breakdown by plasma and liver cholinesterases into the less toxic
metabolites benzoylecgonine (BE) and ecgonine methyl ester (EME) which are water
soluble and excreted into the urine. " Despite its reduced toxicity, EME has been
shown to be detrimental to cardiovascular function during pregnancy.18 Norcocaine (NC)
is a minor N-demethylation species generated by liver P450 enzymes and constitutes less
than 5% of the total metabolites.15'19 However, NC may be important in prolonging some
of the effects of cocaine since it is reabsorbed by enterohepatic circulation and still has
significant toxicity and pharmacological activity.15'17'20
Subjective Effects
The desired effects of cocaine have a variable time course of onset and duration
depending upon the route of administration. Smoking causes the most rapid onset, taking
only a few seconds, however the effects last for only a few minutes.10 Snorting and oral
administration have a more delayed onset, but the effects can last for several minutes to
a few hours.10 Users frequently report feelings of exhilaration, euphoria, alertness,
enhanced libido, and increased self-confidence.4'11' '
The undesired effects of cocaine are highly variable depending upon the individual
and may include overwhelming anxiety, irritability, displaced thinking, cardiovascular
complications, and death.10'11'21 After cessation of use, unpleasant withdrawal symptoms
usually appear in two stages. Stage one, or acute withdrawal, involves feelings of

depression, agitation, distress, and paranoia.4'11'21 Stage two, or prolonged withdrawal,
involves decreased motivation, boredom, anhedonia, and intense cravings for cocaine
that can be triggered or heightened by environmental cues that remind the user of
previous use.21
Addiction is believed to be mediated at least in part by dopamine reuptake
inhibition in the central nervous system including the nucleus accumbens which is part
of the mesolimbic system.22'23 This has the effect of potentiating the actions of dopamine
99

at postsynaptic neurons. In mice homozygous for a defective dopamine transporter
gene, excess dopamine accumulates in extracellular spaces and the animals exhibit
behavioral responses similar to cocaine intoxication.24 It is also believed that serotonin
reuptake inhibition also contributes to cocaine addiction, but with less priority than
dopamine signaling.25
Cardiovascular Toxicity
Cocaine is the leading cause of drug related deaths and cardiovascular
9fi

complications play a major role in this etiology. Asymptomatic heart disease is
97

prevalent among chronic cocaine users, affecting an estimated 38%. As a
sympathomimetic, cocaine is known to cause abnormal increases in heart rate,
98 "\ 1

contractility (inotropy), arterial blood pressure, and coronary artery vasoconstriction.
Decreased coronary flow at a time of increased oxygen demand may cause ischemia in
the myocardium.

In addition, the ability of cocaine to activate blood platelets increases

the possibility of thrombosis formation and subsequent myocardial infarction or
stroke.32-35
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Cocaine can adversely affect the heart indirectly by damaging the kidneys, organs
with critical functional ties to the cardiovascular system. Renal nephrons are the primary
structural and functional subunits of the kidney and are responsible for balancing the
processes of renal filtration, secretion, and reabsorption. By closely regulating these
three processes, the nephron maintains homeostatic control over blood volume and
pressure. Chronic cocaine abuse may lead to hypertension induced proteinuria which
then causes inflammation and dysfunction of proximal tubular epithelial cells of the
nephron.36'37 Cocaine may also cause rhabdomyolysis, a form of muscle fiber destruction
with release of sarcoplasmic proteins, and antibody-mediated glomerulonephritis, further
exposing renal epithelial cells to harmful ultrafiltered proteins.38"43 Rats given daily
intraperitoneal injections of cocaine (30 mg/kg/day) develop severe tubular epithelial
necrosis and glomerular sclerosis over the course of several weeks.44 Ultimately, the
disruption of renal structure and function has deleterious consequences for the heart as it
works to compensate for the ensuing abnormalities in blood volume and pressure.
Direct effects of cocaine on the heart have been described. The aforementioned
anesthetic property of cocaine is related to its ability to inhibit voltage gated sodium
channel conductance.6 In addition, cocaine can selectively potentiate the activity of the
L-type calcium channel.45 Cocaine also interferes with energy metabolism by disrupting
mitochondrial function.46'47 These effects can lead to abnormalities in heart rhythm and
contractility due to the central role of mitochondrial ATP, sodium, and calcium in the
excitation-contraction mechanism of the heart. ATP provides energy for myosin crossbridge cycling and active transport of Ca2+. Disruption in the supply of ATP may cause
reduced myocardial contractility (inotropy) and impair the ability of the heart to relax
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(lusitropy). Sodium is responsible for the initial upstroke of depolarization in the
myocardial action potential. Delayed impulse conduction through the myocardium by
way of sodium channel inhibition may cause an arrhythmia or lethal ventricular
fibrillation. Calcium participates in the plateau-phase of the myocardial action potential,
control of calcium release from the sarcoplasmic reticulum (calcium induce calcium
release), and removal of tropomyosin inhibition to allow for myosin cross-bridge
formation upon actin. Potentiation of calcium channel signaling may prolong action
potential duration which also contributes to arrhythmia formation or ventricular
fibrillation. Elevated calcium may also cause short-term (due to accompanying lack of
ATP) elevation in myocardial contractility and decreased lusitropy. Calcium overload
may also lead to apoptosis via calcinurin mediated dephosphorylation of BAD, release of
cytochrome C from mitochondrial stores, and subsequent caspase activation.48"50
Decreasing numbers of functional cardiac myocytes eventually leads to irreparable
myocardial dysfunction and heart failure.
One important transcription factor suspected to be involved with the
cardiovascular toxicity of cocaine is nuclear factor-kappa B ( N F - K B ) .

NF-KB

is activated

by oxidizing conditions and helps to regulate the expression of genes associated with
inflammation, hypertrophy, and fibrosis.51"55 There is presently limited information
concerning the direct effects of cocaine on N F - K B activity in cardiac myocytes.
However, cocaine has been shown to activate N F - K B in neurons of the nucleus
accumbens, endothelial cells of the cerebral vasculature, and tumor derived adrenal
medullary cells (PC12).56"58 Cocaine also reduces intracellular levels of glutathione, an
important antioxidant, which may tip the redox balance within the cell in favor of net
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free-radical generation.59'60 Free-radicals are highly oxidative molecular or atomic
species that contain an unpaired electron in their orbital structure and have the potential
to activate

NF-KB. 5 1 , 5 2

Current evidence strongly points towards the possibility of cocaine induced NFKB activity in cardiac myocytes. For example, recent studies have described the major
sources of cocaine induced reactive oxygen species (ROS) generation within cardiac
myocytes, namely the enzymes NADPH oxidase and xanthine oxidoreductase. '
Although ROS are potent activators of N F - K B , these studies did not examine that
relationship. Moreover, studies in the rat indicate that cocaine can induce myocardial
inflammation, hypertrophy, and fibrosis, all of which are consistent with

NF-KB

activity.59'63 However, the actual involvement of N F - K B in these studies was not
measured.
Our Previous Studies With Cocaine
Our laboratory has examined the effects of cocaine and its metabolite EME on the
adult and fetal rabbit cardiovascular system. Evidence indicates that the pregnant female
and her fetus are more susceptible to the effects of cocaine than the male or nonpregnant female.18'64'65 Intravenous injection of cocaine (2 mg/kg) increases mean
arterial pressure (MAP) and blood CO2 concentration (PCO2), but decreases blood pH
and O2 concentration (PO2) in both males and pregnant females, indicating increased
sympathetic cardiovascular stimulation with concurrent hypoxemia. Cocaine also
increases plasma renin activity (PRA) in pregnant females, but not in males an effect that
may be attributed to the different hormonal environments caused by pregnancy. The
increase in PRA suggests an increase in angiotensin II, a powerful vasoconstrictor linked
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to hypertension, myocardial hypertrophy, and heart failure. Intravenous injection of
EME (2 mg/kg), which is a major metabolite of cocaine in rabbits, increases MAP and
PRA in pregnant females, but does not affect pCCh or pCh, indicating that this
metabolite has significant sympathomimetic activity, but lacks the hypoxemic properties
of the parent compound.
Experiments have been performed using the Langendorff isolated perfused heart
method to assess the effects of chronic exposure of the rabbit heart to cocaine, EME, or
vehicle, and to the stress of global ischemia.18 Our data indicates that hearts exposed to
cocaine or EME and then stressed with global ischemia demonstrate a significant
decrease in coronary flow, left ventricular pressure, and heart work index during the
period of reperfusion than hearts exposed to vehicle (0.9% sodium chloride). These
studies in vitro and in vivo suggest that cocaine and its metabolite EME alter
cardiovascular function by increasing left ventricular pressures, and in the presence of
ishemia-reperfusion, decrease coronary flow to the heart and thus reduce the work
performance of the left ventricle. However, the mechanisms used by cocaine to reduce
left ventricular performance are unclear. Therefore, the current studies have been
performed to help add to our understanding of the mechanisms involved with cocaine
induced cardiac toxicity and dysfunction.

ECSTASY

Background
3,4-Methylenedioxymethamphetamine (MDMA) is another popular and illicit
psychoactive drug taken for its mood altering and stimulating effects. MDMA is a
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favorite party drug among teens and young adults and often goes by the street name
"ecstasy." A recent government estimate places the lifetime use of MDMA among
United States teens at approximately 4.1%, making it slightly less used than cocaine, but
over 3 times more prevalent than heroin.3 Although considered safe and enjoyable by
many users, current evidence suggests that this drug may also be detrimental to multiple
internal organs including the heart.
MDMA shares molecular similarities with its parent compound amphetamine and
the hallucinogenic substance mescaline.66 An aromatically integrated methylenedioxy
group is critical to its hybridized structure. The term "designer drug" is often used to
describe this substance since the synthesis of MDMA deliberately merges the
physiologic and psychotropic properties of both amphetamine and mescaline into one
compound. MDMA is currently registered as a schedule I compound with the DEA of
the United States, denoting its high abuse potential and current lack of legitimate
medical use.
Toxicodynam ics
MDMA is mostly taken orally in tablet form. A common recreational dose can
range from 50 to 150 mg, although the exact amount of MDMA and the presence of
contaminants in each tablet can vary greatly depending upon the manufacturer.66 A binge
pattern of self-administration is characteristic of most users. This typically entails two
or three consecutive days of drug abuse, usually a weekend, followed by several days of
abstinence, recovery, and then repetition of the cycle. In addition, MDMA is more likely
to be taken at social gatherings (ie. parties) as opposed to isolated solitary use.
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In a study involving healthy human volunteers, single oral administrations of 75 or
125 mg of MDMA gave rise to peak plasma concentrations of 131 and 236 ng/ml
respectively.69 Peak levels were observed approximately 2 h after ingestion with an
elimination half-life on the order of 8 h. Since approximately 6 half-lives are required for
98% clearance of any drug, it takes about 48 h to obtain this level of clearance for
MDMA.
In the liver, cytochrome P450 enzymes known as CYP1A2, CYP2D6, and
CYP3A4 are the main contributors to MDMA catabolism.70'71 These enzymes lead to
demethylenation into metabolites such as 3,4-dihydroxymethamphetamine (HHMA) and
3,4-dihydroxyamphetamine (HHA) followed by urinary elimination as glucuronide or
sulphate conjugates. Evidence suggests that these enzymes may become saturated or
non-productively complexed with MDMA as the dose is steadily increased, even within
the recreational range, causing a non-linear and disproportional elevation in plasma
concentration relative to actual intake. ' This means that at a certain threshold, which
may vary from person to person, a small increase in MDMA administration may lead to
a sudden and large rise in plasma levels, causing acute toxicity in unsuspecting
individuals.
Subjective Effects
The desired effects of MDMA usually appear within one or two hours after
ingestion, which coincides with rising and peak plasma concentrations.66 Users often
report an increased sense of alertness, energy, well-being, sociability, and feelings of
great empathy towards others.66'73'74 The terms "enactogen" or "empathogen" are often
applied to drugs like MDMA in order to better describe their distinctive psychotropic
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properties. Reports of enhanced sexual desire are also common in both genders, although
consummating the act of intercourse may be difficult while under the influence since
MDMA may cause erectile dysfunction in males.75
The undesired effects of MDMA are highly variable depending upon the
individual and may include hyperactivity, confusion, anxiety, bruxism (tooth grinding),
dry mouth, nausea, vertigo, delirium, psychosis, and death.66'73'74'76 The moderately long
half-life contributes to the lingering side-effects experienced by some individuals in the
days following drug use, which may include fatigue, anxiety, depression, and difficulty
in concentrating.74 Although a certain degree of psychological addiction is readily
apparent, it is believed that physical addiction to MDMA, in the traditional sense, is
highly unlikely due to the decrease in desired effects and increase in undesired effects if
the drug is used too frequently. '
Many of the psychological and physical effects of MDMA are related to its ability
to increase the net concentrations of serotonin and norepinephrine at neuronal terminals
by subverting the transport mechanisms involved with synaptic reuptake.77'78 With
abnormal release patterns and impaired synaptic clearance, these neurotransmitters
improperly and extensively stimulate various post-synaptic targets, including regions of
the brain and sympathetic end-organs in the periphery.66'79 Elevated serotonin levels
account for many of the mental components of MDMA intoxication, while the physical
effects are mainly related to increased norepinephrine signaling.66 Damage to various
organ systems can occur because of the abnormal neurotransmitter accumulation and by
the direct and indirect actions of MDMA and its metabolites.
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Cardiovascular Toxicity
Several adverse cardiovascular effects of MDMA have been observed. In
otherwise healthy humans, MDMA can cause abnormal increases in heart rate, mean
80

arterial pressure, and myocardial wall stress. In rats given regular binge pattern
intravenous administration of MDMA, increased inflammatory infiltration and lesioning
of the myocardium can develop within a few weeks.67 This type of administration can
also cause significant and progressive bradycardia with accompanying hypotension.67
Autonomic dysregulation is suspected to contribute to the abnormalities in heart rhythm
and blood pressure seen with MDMA abuse and may involve increased net release of
norepinephrine from pre-synaptic terminals followed by a- and P-adrenergic receptor
81 83

interaction.
Direct effects of MDMA induced cardiovascular toxicity have also been
observed. In cultured rat cardiac myocytes, MDMA metabolites alpha-MeDA and NMe-alpha-MeDA, both with free radical generating potential, show a higher level of
84.

cytotoxicity compared to the parent compound. This finding reveals the importance of
the peripheral metabolism of MDMA into more toxic forms. In isolated Purkinje fibers,
MDMA can abnormally prolong action potential duration, a key component of cardiac
rhythmicity.85 In tumor derived adrenal medullary cells (PC 12), treatment with MDMA
for 24 h abnormally elevates intracellular Ca2+.86 If cardiac myocytes are affect by
MDMA in a similar manner, this finding will have important implications for the intact
4.8 87 88

heart including myocardial arrhythmia, hypertrophy, fibrosis, and apoptosis. ' '
Other lines of evidence illustrate both the direct and indirect cardiotoxic effects of
MDMA. It is well known that the serotonin release enhancing substance fenfluramine,
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one of the active ingredients in the banned diet aid Fen-Phen, can induce serotonin 2B
(5-HT2B) receptor mediated valvular interstitial cell fibroplasia and subsequent heart
failure.89 MDMA has a similar effect on heart valves by acting as a direct agonist to the
5-HT2B receptor.90 Furthermore, overexpression of 5-HT2B receptors in the
myocardium leads to abnormal hypertophy and mitochondrial dysfunction.91 Since
MDMA also enhances net serotonin release from peripheral stores, the potential for
5-HT2B receptor agonism and subsequent myocardial hypertrophy, fibrosis, and
dysfunction is very high with this compound.
Currently, there is very little information concerning the direct effects of MDMA
on the heart as it pertains to redox balance, N F - K B activity, or intracellular Ca
homeostasis. One study showed that MDMA can increase ROS production and deplete
reduced glutathione levels in hepatic stellate cells. Another study indicates that
MDMA can increase hydroxyl radical formation in the rat brain. Theoretically, the
oxidative environments imposed by MDMA administration in these studies represent
ideal conditions for N F - K B activation and subsequent upregulation of downstream
genes, including those involved with the inflammatory response. There is already
evidence that links MDMA administration to increased nitrotyrosine content of proteins
(an index of ROS activity) within the left ventricle, as well as increased lymphocyte
infiltration and inflammatory damage to the myocardium (myocarditis).67'94 However,
the degree of N F - K B involvement with these responses remains unknown.
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NUCLEAR FACTOR-KAPPA B
Background
Nuclear factor-kappa B ( N F - K B ) is an important and ubiquitous transcription
factor found most commonly as a heterodimer consisting of p50 and p65 subunits. It was
first discovered in isolated nuclear fractions as a protein bound to the kappa light chain
immunoglobulin-enhancer sequence in B cells.95 It has since been found in a wide
variety of other cell types and shown to be a critical regulator of many biological
responses including inflammation, growth, and cell survival.
One important organ affected by N F - K B signaling is the heart. The highly aerobic
tissues of the heart are particularly susceptible to oxidizing conditions and cytokine
exposure, important stimulators of N F - K B activity. Recent studies have shown that
many common pathological conditions of the heart such as ischemia-reperfusion,
hypertrophic remodeling, and contractile dysfunction are intimately tied to the activation
status of this transcription factor and the expression of downstream target genes under its
control.
NF-KB

Structure
The NF-kB transcription factors are made up of five closely related protein

subunits: p50, p52, p65, cRel, and RelB. These proteins unite in various combinations
to form fully functional homodimers and heterodimers, the most common and
transcriptionally active of which is the p50-p65 complex.97 All N F - K B proteins contain a
conserved Rel homology region (RHR) which is responsible for subunit dimerization,
inhibitor binding, sub-cellular localization, and sequence-specific DNA recognition.97'98
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The overall architecture of each N F - K B protein consists of two immunoglobulinno

like domains joined by a flexible 10-residue segment. Dimer formation occurs by way
of contacts at the C-terminal dimerization domains on each subunit, giving rise to a
distinct P-sheet sandwich motif held together by hydrophobic clustering and polar
interactions.98 The juxtaposition of certain similarly charged residues upon homodimer
formation makes heterodimer formation energetically more favorable, which helps to
no

explain why the p50-p65 complex is so abundant and ubiquitous among cell types.
The prototypical p50-p65 heterodimer recognizes specific DNA sequences by way
OS

of structural loops emanating near the N-terminal and C-terminal domains. In X-ray
diffraction experiments of co-crystallized

NF-KB

and DNA, it has been determined that

the consensus sequence consists of 5'-GGGRNYYYCC-3', where R is a purine, Y is a
pyrimidine, and N can be any nucleotide.98 It has also been found that the five base-pairs
in contact with p50 (5'-GGGRN-3') are strictly conserved while the four base-pairs in
contact with p65 (5'-YYCC-3') tend to be more variable, allowing for some diversity in
the recognition of promoter sequences from different genes. Significant conformational
changes in both subunits are observed upon regulatory protein binding and DNA
interaction.
NF-KB

97.99

Regulation
Under basal conditions, N F - K B is sequestered in the cytoplasmic compartment by

binding to the IKB family of inhibitory proteins, the most common and biologically
active of which is iKBa.97'99 The binding of IicBa to N F - K B causes a drastic
conformational change in the transcription factor and access to the nuclear localization
sequences in the RHR becomes sterically blocked.97'99 This effectively inhibits nuclear
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importation and subsequent activation of downstream dependent genes. In addition, the
nuclear export sequence on IicBa, which is part of a negative feedback regulatory loop,
helps to retrieve and remove N F - K B from the nucleus.100
Activation of N F - K B occurs when

IKBO.

becomes phosphorylated on a pair of

critical N-terminal serine residues.101 This action is followed by polyubiquitination
which targets MBa for the 26S proteasome where it is degraded.101"104 Removal of

IKBO.

uncovers the nuclear localization sequences on N F - K B , which is then free to migrate into
the nucleus where it can bind to KB-response elements in the promoter and enhancer
r

•

101-103

regions of various genes.
NF-KB

can be activated by a wide variety of intrinsic and extrinsic stress signals.

Some of the known stimulators of N F - K B activity include reactive oxygen species
(ROS), ionizing radiation, tumor necrosis factor alpha (TNFa), interleukin-1 beta
(IL-1(3), interleukin-6 (IL-6), and bacterial lipopolysaccharides.103'105"107 Some of the
aforementioned stimulators of N F - K B activity (ie. the cytokines) are actual downstream
targets of N F - K B mediated transcription.106 It is therefore reasonable to predict that
under the appropriate conditions, N F - K B activation may lead to a sustained positive
feedback loop that amplifies the expression of certain inflammatory mediators.
The detailed mechanisms of N F - K B activation and signal transduction are still
under intense investigation. However, it is clear that multiple pathways exist depending
upon the type of stimulus involved. For example, in many cells, DNA-dependent protein
kinase (DNA-PK) is a serine/threonine kinase that responds to and helps repair double
stranded DNA breaks.103 Upon inhibition of DNA-PK, TNFa retains while ionizing
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radiation loses its ability to activate NF-KB. 1 0 3 In cardiac myocytes, toll-like receptor 2
(TLR2) is involved with the innate immune response to certain bacteria.108 When this
receptor is blocked by anti-TLR2 antibodies, TNFa retains while hydrogen peroxide
loses its ability to activate

NF-KB. 1 0 8

Although there is obvious diversity in the upstream signaling pathways that lead to
NF-KB

activation, a convergence exists at the level of IKBO. phosphorylation and

degradation. IKB kinase (IKK) is a multienzyme complex containing IKKot, IKK|3, and
IKKy subunits.104 This enzyme phosphorylates the critical N-terminal serine residues on
IKBOC which

are responsible for its eventual degradation and release of NF-KB. 1 0 4 IKK is

believed to be a convergence point immediately upstream of N F - K B activation, serving
to unify the signaling pathways of many different stimuli known to activate

NF-KB.

However, since its own activity is regulated by phosphorylation, the exact set of protein
kinases that may be involved in activating IKK and how they themselves are regulated
remains to be fully characterized. One such IKK-kinase has already been described
called NF-KB-inducing kinase (NIK), a member of the mitogen-activated protein kinase
kinase kinase (MAPKKK) family.102'104 Transforming growth factor beta-activated
kinase 1 (TAK1) is yet another IKK-kinase and its activity has been shown to be
regulated by protein kinase C beta (PKC|3).109
Cardiac

NF-KB

Studies have shown that N F - K B activity in the heart is associated with both
detrimental and beneficial effects. The downstream genes controlled by N F - K B are
diverse and include inflammatory cytokines, intercellular adhesion molecules, signaling
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enzymes, and regulatory proteins.106'107'110 The net effect of N F - K B signaling in the heart
is highly dependent upon the context of activation which in turn determines whether or
not the response is compensatory or maladaptive.
In cultured cardiac myocytes, the ROS generating compound hydrogen peroxide
can activate N F - K B . 5 2 Myocardial intracellular adhesion molecule-1 (ICAM-1) and
vascular cell adhesion molecule-1 (VCAM-1) are proteins important for leukocyte
binding and infiltration into the myocardium and are associated with inflammation and
subsequent myocardial damage.110 ICAM-1 and VCAM-1 gene expression is effectively
reduced in the presence of N F - K B inhibitors.110'111 Free radical oxidative stress can
activate N F - K B and lead to increased cytokine and adhesion molecule expression with
subsequent neutrophil infiltration into the myocardium.112'113 In biopsies of patients with
end-stage congestive heart failure, N F - K B has been co-localized with the prostanoid
producing enzyme cyclooxygenase-2 (COX-2) in areas of the myocardium riddled with
inflammation and fibrotic scar formation.

Some evidence suggests that this response

can be mitigated with antioxidant administration.114
One of the most frequently encountered heart conditions is the phenomenon of
ischemia-reperfusion. Ischemia occurs when the blood supply to heart tissue becomes
greatly impaired or fully blocked, causing a hypoxic condition which, if sufficiently
sustained, can cause irreversible damage to the myocardium.96 This may happen during a
heart attack or coronary artery vasospasm. Reperfusion is a period of renewed blood
flow at significantly increased or near normal levels with a corresponding delivery of
oxygen back into the myocardium.96 This may occur during anticoagulant treatment after
a heart attack or immediately after a coronary artery vasospasm subsides. Although
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reperfusion is ideal and necessary to counter the ultimate effects of ischemia, the sudden
reintroduction of oxygen to a hypoxic myocardium is known to cause the generation of
ROS.113
In sufficient quantities, ROS alone can cause cellular damage, death, and
myocardial dysfunction.96'113 ROS is also a powerful stimulator of the N F - K B pathway.
In a study by Chandrasekar et al., the effects of ischemia-reperfusion were observed in
i n

the rat heart.

In their model, the left anterior descending coronary artery was ligated

for 45 min and then reperfused for various time points up to 6 h. Compared to control
animals, the myocardium of ischemia-reperfusion animals had significantly increased
levels of ROS, N F - K B activity, TNFa, and IL-lp\ In addition, histological examination
revealed increased neutrophil infiltration concentrated in areas of the myocardium
directly affected by the ischemia-reperfusion. Neutrophils are the predominate class of
phagocytic leukocytes during the early stages of inflammation.96 They are responsible
for causing tissue damage upon their death and subsequent release of cytoplasmic
contents, including powerful lysosomal enzymes.96
In another study by Fan et al., the effects of ischemia-reperfusion were observed in
the dog heart.115 In their model, the left anterior descending coronary artery was
occluded by an inflated angioplasty balloon for 90 min and then reperfused for either 1
or 3 h thereafter. Some animals were treated with the ROS scavenger N-(2mercaptopropionyl)-glycine (MPG) 5 min prior to reperfusion. It was found that

NF-KB

activity and ICAM-1 expression were significantly elevated in ischemia-reperfusion
animals that did not receive MPG. This finding illustrates the connections between ROS
generation, N F - K B activation, and downstream expression of ICAM-1, an important
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adhesion molecule known to mediate myocardial injury by recruiting neutrophils to the
area.110'115
Another frequently encountered condition, especially in the chronically stressed
and/or failing heart, is myocardial hypertrophy. This condition is characterized by
enlargement and increased fibrotic remodeling of the myocardium which increases the
risk for ischemia-reperfusion, ventricular fibrillation, and death due to cardiac
arrest.96'116 Elevated circulating catecholamines and persistent P-adrenergic receptor
stimulation are known to be major causes of myocardial hypertrophy and N F - K B activity
has been shown to be involved with this response.117 Additional evidence in cultured
ventricular myocytes suggests that N F - K B activity is required for the hypertrophy caused
by other well known inducing agents such as phenylephrine (an a-adrenergic receptor
agonist), endothelin-1, and angiotensin II.54 In transgenic mice designed to overexpress
cardiac myotrophin, suppression of N F - K B activity blocks the development of the
hypertrophic phenotype normally induced by this gene.118'119
Abnormal induction of apoptosis is another pathological condition that can affect
cardiac function. Apoptosis is a normal part of prenatal development, but if it occurs to a
significant extent in tissues with limited capacities to regenerate (ie. myocardial tissue)
irreparable functional losses may result.96 N F - K B is believed to exert a pro-survival
influence in the heart by preventing apoptosis. An important study by de Moissac et al.
was the first to suggest a link between the anti-apoptotic protein Bcl-2 and N F - K B in
cultured ventricular myocytes.

In their model, Bcl-2 activated N F - K B by enhancing

proteasomal breakdown of IKBCC. It has also been observed that Bcl-2 loses its antiapoptotic properties in cardiac myocytes inhibited for N F - K B activation.121 Moreover, in
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cultured ventricular myocytes transfected with a non-degradable form of IKB, TNFa
exposure resulted in significantly increased apoptosis, implying that a functional

NF-KB

pathway is necessary to prevent apoptosis.122 Survival in the face of pro-apoptotic
signals is essential in the progression of hypertension induced ventricular hypertrophy
and heart failure where TNFa and circulating catecholamines are chronically
elevated.54'123'124
Cardiac N F - K B activity does not always lead exclusively to detrimental effects. In
some cases, a compensatory component to the overall response is evoked. For example,
evidence in rats indicates that oxidative stress due to systemic inhalation hypoxia
activates N F - K B which then upregulates the expression of vascular endothelial growth
1 9S 1 Oft

factor (VEGF) in the myocardium.

'

VEGF is an important angiogenic factor that

promotes new blood vessel growth in order to counteract the effects of hypoxia.125'1

6

Upon subjecting these hypoxic preconditioned rats to myocardial infarction, it was
observed that the contractile ability of the heart was significantly preserved compared to
control animals that did not receive hypoxic preconditioning. This finding demonstrates
a beneficial effect of N F - K B signaling within the same organ under different stimulatory
context.
PURPOSE

The current literature indicates that cocaine and ecstasy are detrimental to
cardiovascular homeostasis. However, many details of their effects on the heart have yet
to be fully described. Therefore, our goal in performing these studies was to further
characterize the effects of these drugs at the cellular and intact organ system level. We
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predicted that exposure to these drugs would significantly disrupt cellular homeostasis
and normal heart function. To quantify the effects of these drugs, we used both in vitro
and in vivo models in separate experimental designs and measure several homeostatic
parameters including reactive oxygen species generation, intracellular Ca2+ balance,
NF-KB

activity, gene expression, and left ventricular function. We also measured the

effects of different pre-treatment strategies. The information obtained provides more
insight into mechanisms by which the heart is affected when these drugs are used.
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METHODS

EXPERIMENTS WITH COCAINE

Dual-Luciferase Luminometry
In these experiments, we observed the effects of cocaine on N F - K B activity in
cultured cardiac myocytes. Cocaine is a schedule II substance with the Drug
Enforcement Agency (DEA) of the United States and was obtained, stored, handled, and
disposed of in accordance with federal, state, and University regulations by a DEA
licensed investigator (Dr. Barbara Y. Hargrave). H9c2 cells from the rat (Rattus
norvegicus) were cultured in sterile 0.2 urn vented T-75 flasks (Corning). These
embryonic cardiac myoblasts provided an excellent cell model for our studies since they
are known to have an intact N F - K B signaling system and a drug metabolizing enzyme
repertoire similar to adult cardiac myocytes.

'

Cultures were maintained in an

aseptically prepared Sheldon model 2310 incubator (Sheldon Manufacturing) at 37°C,
5% atmospheric CO2, and saturated relative humidity. Culture media consisted of
Dulbecco's Modified Eagle's Medium™ containing 5% fetal bovine serum (FBS). Cells
and media were obtained from American Type Culture Collection (ATCC). DNA
vectors were obtained from Stratagene, Promega, and Dr. Stephen J. Beebe of Eastern
Virginia Medical School. Manipulations involving viable cells were carried out inside a
class II biological safety cabinet using sterile equipment and aseptic technique.
On day 1, after the cells had become approximately 85% confluent, the media in
the T-75 flask was removed and discarded. Adherent cells were loosened by exposure to

2 ml of 0.25% trypsin EDTA (ATCC). After 2 min, the trypsin was removed and
discarded. The cells were then resuspended in 10 ml of fresh media. With the aid of a
hemacytometer (Fisher), approximately 150,000 cells were plated in duplicates onto
each well of a sterile 12-well culture plate (Corning). Enough fresh media was added to
adjust the final volume to 4 ml in each well. The plate was then returned to the incubator
for 24 h.
On day 2, the overlying media was removed and discarded. Next, 2 ml of fresh
media was gently added to each well. The plate was returned to the incubator while the
transfection solution was being prepared. All cells were transfected using the FuGENE®
(Roche) method. This technique involves the use of FuGENE® 6, a sterile-filtered lipidbased transfection reagent that complexes and helps transport DNA into cultured cells.
FuGENE® 6 has low toxicity and provides high transfection efficiency in many cell
types including heart cells. The transfection solution for each well was made in separate
sterile nuclease-free microcentrifuge tubes (Eppendorf). The transfection solution
consisted of 1.0 p,g firefly luciferase DNA coupled to an inducible N F - K B promoter,
0.1 ug Renilla luciferase DNA coupled to a constitutively active SV40 promoter, and
either 1.0 ug pCMV DNA (empty vector) or 1.0 jag IKB DNA coupled to a constitutively
active CMV promoter. To maintain the concentration of transfected DNA constant
across all groups, cells that were not given IKB DNA received the empty pCMV DNA
vector. Enough FBS-free cell culture media (90.7 \x\) and FuGENE® 6
(6.3 (j.1) was added to achieve a total volume of 100 ul and a 3:1 ratio of FuGENE® 6 to
total DNA. The transfection solution was allowed to incubate at room temperature for
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30 min. After incubation, 100 ul of the transfection solution was placed onto the cells by
direct addition to the 2 ml of media already in each well. The plate was then returned to
the incubator for 24 h.
On day 3, the overlying solution was removed and discarded. The cells were then
stimulated with the following concentrations of cocaine: 0 M, 1X10"4 M, 1X103 M, and
1X10"ZM. The drug was dissolved in enough cell culture media to achieve each
concentration and 2 ml of each dose was gently added to the appropriate wells. Cell
culture media alone (without drug) was added to the cells that served as our 0 M
controls. To examine the effects of IKB overexpression on cocaine induced

NF-KB

activity, cells co-transfected with IKB DNA were stimulated with either 0 M cocaine or
the high dose of IX 10"ZM cocaine. Cells serving as controls for this part of the
experiment (0 M + IKB) were exposed to culture media alone (without drug). All cells
were stimulated for 24 h. For a summary of the transfection and drug dosage scheme, see
Tables 1 and 2.

TABLE 1. Transfection Protocol and Drug Dosage Scheme for H9c2
Cells Transfected With NF-KB Reporter and Stimulated With Cocaine
Well#

1
2
3
4
5
6
7
8

(ug)

pRL-SV40
(ug)

PC1V
(ug)

0
0
0
0
0
0
0
0

0.1
0.1
0.1
0.1
0.1
0.1
0.1
0.1

1.0
1.0
1.0
1.0
1.0
1.0
1.0
1.0

Cocaine
(M)

NF-KB

IKB

(ug)

0
0
1X10-4
1X10"4
1X10"3
IX10"3
1X10"2
IX10"2

1.0
1.0
1.0
1.0
1.0
1.0
1.0
1.0
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TABLE 2. Transfection Protocol and Drug Dosage Scheme for H9c2
Cells Co-Transfected With NF-KB Reporter and IKB Overexpression
Vector and Stimulated With Cocaine
Well#

1
2
3
4

PCMV

G*g)

pRL- SV40
G*g)

1.0
1.0
1.0
1.0

0.1
0.1
0.1
0.1

0
0
0
0

Cocaine
(M)

NF-KB

IKB

(ng)

0
0
1X10"2
1X10"2

1.0
1.0
1.0
1.0

fog)

On day 4, the cells were removed from the incubator and placed on ice. The
overlying solution was removed and discarded. The cells were washed with 2 changes of
isotonic phosphate buffered saline (PBS) (pH 7.4) to remove residual drug solution. In
order to lyse the cells, 250 \A of Passive Lysis Buffer (Promega) was placed into each
well. This reagent was designed to lyse cells and stabilize both types of luciferase
enzymes for assay and cold storage. After 15 min, each well was scraped for 30 s with a
sterile cell scraper (Corning) and the lysate transferred into a new separate
microcentrifuge tube. Each lysate was vortexed on high for 30 s and then centrifuged at
14,000X for 3 min. The supernatant (containing luciferase) from each tube was
transferred into a new separate microcentrifuge tube.
To sequentially quantify firefly and Renilla luciferase activities, samples were
analyzed using the Dual-Luciferase™ Reporter Assay System (Promega). All
proprietary reagents were obtained from Promega unless otherwise indicated. An
automated dual-injector luminometer connected to a computer was used to control
reagent delivery, agitate reactants, quantify luminescence, and perform integral
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calculations. 20 ul aliquots of sample were placed into separate wells of an opaquewalled 96-well plate (Corning) in duplicates. One-hundred ul of Luciferase Assay
Reagent was injected and the integral sum of firefly luciferase activity was measured
over a 5 s read time. Next, 100 ul of Stop & Glo Reagent was injected and the integral
sum of Renilla luciferase activity was measured over a 5 s read time. The ratio of firefly
luciferase activity to Renilla luciferase activity was determined and statistical analysis
(single-factor ANOVA followed by Tukey's test) was performed on all data. Table 3
summarizes the overall protocol.

TABLE 3. Summary of the Dual-Luciferase Luminometry Protocol
Day 1

Day 2

Day 3

Day 4

Plating
(150,000 cells
per well)

Transfection
of cells

Stimulation
of cells with
cocaine or
media alone

Lysis
of cells and
analysis of
lysate

In a related set of experiments, we examined the effects of antioxidant pretreatment on cocaine induced N F - K B activity. H9c2 cells were cultured and treated as
previously described with the exception that on day 3 the cells were pre-treated with
either 1 mM glutathione (Glut), 1 mM N-acetyl-L-cysteine (NAC), or 1 mM Glut +
1 mM NAC for 15 min. The antioxidants were dissolved in enough cell culture media to
achieve each concentration and 2 ml of each dose was gently added to the appropriate
wells. Following pre-treatment, the overlying antioxidant solution was removed and
discarded. The cells were then exposed to the high dose of 1X10" M cocaine for 6 h.
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A O M a n d l X K T M cocaine group without any pre-treatment served as controls.
Reactive Oxygen Species Assay
In these experiments, we observed the effects of cocaine on ROS generation in
cultured cardiac myocytes. H9c2 cells were grown and maintained as described in our
luminometry experiments. The green fluorescent indicator 2',7'-dichlorofluorescin
diacetate (Molecular Probes) was used to measure the presence of drug induced ROS
generation. On day 1, with the aid of a hemacytometer, approximately 150,000 H9c2
cells were plated onto a sterile multi-well culture plate (Corning). The cells were then
returned to the incubator for 24 h.
On day 2, the overlying media was removed and discarded. The cells were washed
with 1 ml of Hank's Media (ATCC) in order to remove residual cell culture media which
contains a red coloring that might interfere with the indicator. Afterward, each well was
given 1 ml of new Hank's Media. Indicator solution was made by dissolving enough
2',7'-dichlorofluorescin diacetate to yield a 5% solution in dimethyl sulfoxide (DMSO)
(Sigma). To load the cells, 1 ml of the indicator solution was added to each well and the
culture plate was gently swirled for 1 min. The culture plate was then wrapped in
aluminum foil and returned to the incubator for 30 min.
Following the loading period, the cells were washed twice with 1 ml of Hank's
Media to remove excess indicator not taken up by the cells. Next, 2 ml of fresh Hank's
Media was placed into each well and the plate was returned to the incubator for 30 min
prior to drug administration. The following concentrations of cocaine were tested:
1X10"4 M, 1X10"3 M, and 1X10"2 M. The drug was dissolved in enough Hank's Media to
achieve each concentration and 2 ml of each dose was gently added to the appropriate
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wells. Just prior to drug exposure, each well was photographed to obtain a baseline
signal. This allowed each well to serve as its own 0 M control. The cells were imaged
using a Zeiss model 510 LSM confocal microscope (Carl Zeiss) equipped with a variable
wavelength argon laser, epifluorescent filters, and a digital camera. Cells generating
ROS exhibited a quantifiable green fluorescence. Images were captured 2 and 5 min
after drug exposure and then analyzed by the program Metamorph (Universal Imaging)
for densitometry.
In a related set of experiments, we examined the effects of antioxidant, Ca
channel blocking, and P-adrenergic receptor blocking pre-treatment on cocaine induced
ROS generation. H9c2 cells were cultured and treated as previously described with the
exception that on day 2, the cells were pre-treated with either 1 mM NAC, 10 uM
verapamil, 10 uM nifedipine, or 10 uM nadolol for 30 min. Following pre-treatment, the
cells were exposed to the high dose of 1X10" M cocaine. Images were captured 2 and
5 min after drug exposure with a Zeiss model 510 LSM confocal microscope and then
analyzed by Metamorph for densitometry.
Intracellular Calcium Assay
In these experiments, we observed the effects of cocaine on intracellular Ca2+
levels in cultured cardiac myocytes. H9c2 cells were grown and maintained as described
in our luminometry experiments. On day 1, with the aid of a hemacytometer,
approximately 150,000 cells were plated onto a sterile multi-well culture plate. The cells
were then returned to the incubator for 24 h. On day 2, the overlying media was removed
and discarded. The fluorescent calcium indicator fluo-3 (Sigma) was dissolved in
enough DMSO to achieve a 1:1000 dilution. The indicator solution was placed onto each
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well and the plate was returned to the incubator for 30-60 min. The cells were then
washed twice with 1 ml of Hank's Media to remove excess indicator. The following
concentrations of cocaine were tested: 1X10"5 M, 1X10"4 M, 1X10"3 M, and 1X10"2 M.
The drug was dissolved in enough Hank's Media to achieve each concentration and 2 ml
of each dose was gently added to the appropriate wells. Just prior to drug exposure, each
well was photographed to obtain a baseline signal. This allowed each well to serve as its
own 0 M control. Images were captured 2 and 5 min after drug exposure with a Zeiss
model 510 LSM confocal microscope and then analyzed by Metamorph for
densitometry.
In a related set of experiments, we examined the effects of Ca

channel blocker

pre-treatment on cocaine induced intracellular Ca2+ levels. H9c2 cells were cultured and
treated as previously described with the exception that on day 2, the cells were pretreated with either 10 uM verapamil or 10 uM nifedipine for 30 min. Following pretreatment, the cells were exposed to either IX10"4 M, IX10"3 M, or 1X10"2 M cocaine.
Images were captured 2 and 5 min after drug exposure with a Zeiss model 510 LSM
confocal microscope and then analyzed by Metamorph for densitometry.
In another related set of experiments, we examined the effects of antioxidant pretreatment on cocaine induced intracellular Ca levels. H9c2 cells were cultured and
treated as previously described with the exception that on day 2, the cells were pretreated with 1 raM NAC for 30 min. Following pre-treatment, the cells were exposed to
either IX10"5 M, 1X10"4 M, 1X10"3 M, or 1X10"2 M cocaine. Images were captured 2
and 5 min after drug exposure with a Zeiss model 510 LSM confocal microscope and
then analyzed by Metamorph for densitometry.
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Gene Array
In these experiments, we characterized the genetic response of H9c2 cells and
rabbit myocardium after acute exposure to cocaine. GEArray™ Q Series Kits
(SuperArray) were used for assessing the transcription levels of certain genes after
exposure to cocaine. A 96-well array containing genes important to cardiovascular
pathology was used — Mouse Cardiovascular Disease Biomarkers. A different 96-well
array containing genes important to cell signaling was also used — Mouse cAMP/Ca +
Signaling Pathway Finder. A list of all genes and their exact location on each array can
be found in the appendix or on the SuperArray website (www.superarray.com).
H9c2 cells were cultured as described in our luminometry experiments. On day 1,
after becoming approximately 85% confluent, each T-75 flask was treated with either
0MorlX10" 2 M cocaine drug solution for 24 h. The drug was dissolved in enough cell
culture media to achieve each concentration and 10 ml of each dose was gently added to
the appropriate flask. On day 2, adherent cells were loosened by exposure to
2 ml of 0.25% trypsin EDTA. After 2 min, the trypsin was removed and discarded. The
cells were then resuspended in 10 ml of PBS (pH 7.4) and then centrifuged at 2,000X for
5 min at 4°C. In order to remove residual trypsin, cellular pellets were again resuspended
in 10 ml of PBS and then centrifuged at 2,000X for 5 min at 4°C. After removal of the
supernatant, the pellets were processed for RNA extraction.
To extract total cellular RNA, a Trizol® Reagent (Life Technologies) based
protocol was used. All steps were performed in a 7°C cold room unless otherwise
indicated. Tissues harvested from the functional experiments were cut into 1 cm cubes
and homogenized on ice under 1 ml Trizol® using a Brinkmann Polytron homogenizer
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(Brinkmann Instruments) while H9c2 pellets were exposed to 0.3 ml Trizol® and mixed
by inversion. Next, 0.5 ml chloroform (Sigma) was added to each tube for tissue
specimens while 0.1 ml chloroform was added to each tube for cell pellets. All tubes
were mixed by brisk shaking for 15 s and then allowed to settle for 2 min. Afterward, all
tubes were centrifuged at 12,000X for 10 min. The supernatant (containing RNA) was
carefully removed and placed into separate sterile nuclease-free microcentrifuge tubes.
To precipitate the RNA, an equal volume of 100% isopropanol (Sigma) was added to
each tube. After centrifugation at 12,000X for 10 min, the supernatant was removed and
discarded. The RNA pellet was then resuspended in an equal volume of 70% ethanol
(Sigma) made in sterile nuclease-free water (HyClone) and centrifuged again at 12,000X
for 5 min. Afterward, the supernatant was removed and discarded. The RNA pellet was
air dried at room temperature until most of the visible moisture was evaporated. The
pellet was then reconstituted with 50 \xl of sterile nuclease-free water followed by brief
heating in a 55°C water bath to help redissolve the pellet. A 5 ul sample was quality
checked on a 1% agarose gel containing 10 ul/100 ml GelStar® Nucleic Acid Gel Stain
(Cambrex) under UV illumination. RNA concentration was determined by
spectrophotometry (A260 nm). All RNA was stored at -80°C until use.
A cDNA probe was made from the isolated RNA using a separate annealing and
labeling procedure. All proprietary reagents were obtained from SuperArray unless
otherwise indicated. For the annealing mix, 2 ug of RNA from each group was added to
3 ul of Buffer A in a sterile nuclease-free PCR tube (Fisher). Enough sterile nucleasefree water was added to fill each tube with 10 ul of total solution. The contents were
then mixed gently with a pipette and the tubes were incubated in a thermocycler at 70°C
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for 3 min, followed by 42°C for 2 min. For the labeling mix, 8 JLXI of Buffer BN was
combined with 4 ul Biotin-16-dUTP (Roche), 2 ul RNAse Inhibitor Solution, 2 ul
Reverse Transcriptase Solution (50 U/ul), and 4 ul sterile nuclease-free water. The
contents were stirred gently with a pipette and the tube was incubated at 42°C for 2 min.
10 ul of labeling mix was added to each annealing mix and the tubes were incubated at
42°C for 90 min. The labeling reaction was stopped by adding 2 ul of Buffer C. In order
to block non-specific binding, 3 ml of heat denatured Sheared Salmon Sperm DNA
Solution (100 ug/ml) was added to the hybridization tubes containing the arrays. The
tubes were then incubated in a hybridization oven for 2 h at 60°C with continuous
agitation at 10 RPM (pre-hybridization step). Labeled cDNA probes were denatured by
heating to 94°C for 5 min and then quickly chilling on ice. After pre-hybridization, the
denatured probes were added to the appropriate hybridization tubes. The tubes were then
incubated in a hybridization oven for 48 h at 60°C with continuous agitation at
10 RPM.
For chemiluminescent detection, the arrays were washed twice with 5 ml of a
solution containing 2X saline-sodium citrate (SSC) (Promega) and 1% sodium dodecyl
sulfate (SDS) (Sigma) — 15 min per wash at 60°C with continuous agitation at 20 RPM.
The arrays were then washed with a 5 ml of a solution containing 0.5X SSC and 0.5%
SDS — 15 min per wash at 60°C with continuous agitation at 20 RPM. This slightly less
stringent secondary wash (normal protocol uses 0.1X SSC and 0.5% SDS) was
necessary for the optimal hybridization of inter-species cDNA (rat-mouse or rabbitmouse). Next, the arrays were exposed to 2 ml Blocking Solution Q for 40 min at room
temperature with continuous agitation at 20 RPM. The arrays were then incubated with
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2 ml Alkaline Phosphatase-Conjugated Streptavidin Solution (diluted 1:7,500 in Buffer
F) for 10 min at room temperature with continuous agitation at 10 RPM. Afterward, the
arrays were washed 4 times with 4 ml Buffer F — 5 min per wash at room temperature.
The arrays were then incubated with 1 ml CDP-Star Chemiluminescent Substrate for
2 min at room temperature. Excess substrate was blotted off gently with clean filter
paper and the arrays were placed into transparent plastic bags for imaging.
The arrays were photographed using a dark-chamber digital imaging system
(BioRad) with computer interface. The image analysis sofware Quantity One (BioRad)
was used to quantify chemiluminescent signals for each spot on the array. Raw data was
exported into an Excel (Microsoft) spreadsheet and then analyzed using the GEArray
Analyzer software downloaded from the SuperArray website (www.superarray.com). As
per manufacturer's suggestions, all signals were background subtracted from the blank
on the array and normalized to the constitutively expressed housekeeping gene
glyceraldehyde-3-phosphate dehydrogenase (GAPDH). Genes with a signal ratio greater
than 2.0 or less than 0.5 (experimental/control) were considered upregulated or
downregulated respectively.
To verify the results, RT-PCR was performed utilizing primer kits obtained from
SuperArray. Since it was not feasible to perform this procedure for all 96 genes on the
array, only a few genes from each array were chosen. SingleGene™ PCR kits
(SuperArray) for the following genes were used: Tnni3, ANG, and KCNA5. First-strand
cDNA was made from the total RNA isolated in each experiment. To optimize the
resolution obtained from the different primers, a temperature-gradient PCR was
conducted with annealing temperatures ranging from 50°C to 65°C. Once the optimal
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annealing temperature was identified for each specific primer pair, that temperature was
used for all subsequent PCR analysis involving those primers. One set of primers in each
primer pair was specific for the array gene being analyzed. The other set of primers was
specific for glyceraldehyde-3-phosphate dehydrogenase (GAPDH), a housekeeping gene
that is constitutively expressed. The PCR products were subjected to electrophoresis on a
2% agarose gel containing 10 ul/100 ml GelStar® Nucleic Acid Gel Stain. The gels were
imaged under a UV illuminator, digitally photographed, and analyzed by the program
Kodak ID (Eastman Kodak Company) for densitometry. The analysis was semiquantitative and ratiometric using the GAPDH signal as an internal normalizer.
Western Blot
In these experiments, we measured the protein level expression of array-specific
genes in H9c2 cells and rabbit myocardium after acute exposure to cocaine. H9c2 cells
were grown and maintained as described in our luminometry experiments. On day 1,
after becoming approximately 85% confluent, each T-75 flask was treated with 10 ml of
either 0 M or 1X10"z M cocaine for 24 hours. The drug was dissolved in enough cell
culture media to achieve each concentration and 10 ml of each dose was gently added to
the appropriate flask.
On day 2, adherent cells were loosened by exposure to 2 ml of 0.25% trypsin
EDTA. After 2 min, the trypsin was removed and discarded. The cells were then
resuspended in 10 ml of PBS (pH 7.4) and then centrifuged at 2,000X for 5 min at 4°C.
In order to remove residual trypsin, cellular pellets were again resuspended in
10 ml of PBS and centrifuged at 2,000X for 5 min at 4°C. After removal of the overlying
PBS, the pellets were subjected to the lysis protocol.
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All pellets were lysed using Radio Immuno Precipitation Assay (RIPA) Lysis
Buffer (Santa Cruz Biotechnology). This technique involves the use of working RIPA
Solution which lyses cells and preserves cellular proteins. All proprietary reagents were
obtained from Santa Cruz Biotechnology unless otherwise indicated. Working RIPA
Solution was made fresh just prior to use by mixing 1 ml RIPA Lysis Buffer with 10 ul
Phenylmethylsulfonyl Fluoride (PMSF) Solution, 10 ul Sodium Orthovanadate Solution,
and 10 ul Protease Inhibitor Cocktail Solution. The working RIPA Solution was added
to each pellet and the cells were resuspended gently with a disposable pipet. After
incubation on ice for 30 min, the resuspension was subjected to hydrodynamic shearing
by forcefully passing the solution through a 21-gauge needle 5 times using a sterile
syringe. After another incubation on ice for 30 min, the resuspension was transferred to
separate protease-free microcentrifuge tubes (Eppendorf) and centrifuged at 8,000X for
10 min in a 7°C cold room. The supernatant (containing cell proteins) was transferred
into new separate protease-free microcentrifuge tubes and stored at -80°C until use.
Protein concentration for each sample was determined using the Bradford assay.
To prepare for Western blotting, samples were diluted in enough sterile proteasefree water (HyClone) to create 65 ul aliquots with an equal total protein concentration of
1,200 ug/ml. All proprietary reagents, gels, and membranes were obtained from
Invitrogen unless otherwise indicated. To each 65 ul aliquot, 25 ul of 4X Lithium
Dodecyl Sulfate (LDS) Sample Buffer and 10 ul of 10X Sample Reducing Agent were
added to create 100 ul of sample solution. The sample solutions were incubated on a
heating block at 100°C for 10 min prior to loading onto the gel. Working running buffer
was made fresh just prior to use by mixing 25 ml of 20X NuPAGE® MOPS Running
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Buffer with 475 ml double-distilled water (ddl-bO). 25 |al of sample solution was loaded
onto the appropriate lanes of a NuPAGE® Novex 4-12% bis-tris polyacrylamide gel
alongside HiMark™ pre-stained protein standard molecular weight markers. 1,250 u,l of
Antioxidant Solution was added to the working running buffer just prior to the
electrophoresis.
The gels were run initially at 200 V and then at 150 V as the tracking dye neared
the bottom of the gel. After electrophoresis, the gels were prepared for transfer to
nitrocellulose membrane. Working transfer buffer was made fresh just prior to use by
mixing 20 ml of 20X NuPAGE® Transfer Buffer with 340 ml ddH 2 0 and 40 ml of 100%
methanol (Sigma). The membrane, gel, and associated filters were stacked in the
appropriate sequence and soaked for 5 min in working transfer buffer while air pockets
were carefully pressed or tapped out. 400 ul of Antioxidant Solution was added to the
working transfer buffer just prior to the electrophoretic transfer which was performed at
30 V for 1 h.
To develop the membranes, a WesternBreeze® Chemiluminescent
Immunodetection Kit (Invitrogen) was used. All proprietary reagents were obtained from
Invitrogen unless otherwise indicated. The membranes were placed in separate clean
polycarbonate trays and incubated with 5 ml Blocking Solution for 30 min at room
temperature. Primary Antibody Solution was made by diluting Mouse Anti-Rabbit IgG
(Santa Cruz Biotechnology) 1:1,000 in Blocking Solution. The primary antibodies were
specific for either BNP, CRP, or TNNI. After blocking, the membranes were rinsed
twice with 20 ml ddEbO — 5 min per rinse. Each membrane was then incubated with 10
ml of Primary Antibody Solution for 24 h at 4°C.
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After primary antibody incubation, the membranes were washed 4 times with
20 ml Antibody Wash — 5 min per wash. Next, the membranes were incubated with
10 ml of Secondary Antibody Solution for 1 h at room temperature. Afterward, the
membranes were washed 4 times with 20 ml Antibody Wash — 5 min per wash. The
membranes were then rinsed 3 times with 20 ml ddt^O — 2 min per rinse. The
membranes were exposed to 2.5 ml Chemiluminescent Substrate for 5 minutes. Excess
substrate was blotted off gently with clean filter paper and the arrays were placed into
transparent plastic bags for imaging. The membranes photographed using the same
imaging system as in the genetic array experiments. Images were analyzed by Quantity
One for densitometry.
Heart Function
In these experiments, we characterized the functional response of the intact heart
to acute cocaine exposure. The New Zealand White (NZW) rabbit (Oryctolagus
cuniculus) was used for this part of the study. All animals were kept under temperature
controlled conditions with automated 12 h light/dark cycles and allowed access to
standard food pellets and water ad libitum. All animals were maintained by the Animal
Care Director and Veterinarian at Old Dominion University's Department of Biological
Sciences housing facility and treated humanely in accordance with federal regulations
(IACUC protocol number 04-014; April 26, 2005).
General anesthesia was induced by giving ketamine (40 mg/kg) and xylazine
(5 mg/kg) intramuscular. After shaving the ventral neck and upper chest hairs, the
animal was placed in the supine position. A longitudinal skin incision over the mid-line
of the trachea was made with a number 10 scalpel. The left common carotid artery was
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carefully isolated from the vagus nerve and surrounding connective tissues. A small
incision was made and a Millar catheter (model SPR-524) (Millar Instruments) was
inserted into the left ventricle via the left common carotid artery. This catheter has a
specialized sensor tip designed for transducing mechanical signals from the
myocardium.
A Digi-Med Heart Performance Analyzer-x model 410 (Micro-Med) was
connected to the Millar catheter. This machine and the accompanying software allows
for the measurement of the following cardiac functional parameters: heart rate (HR) - the
number of left ventricular contractions per minute; maximum pressure (MaxP) - the
highest pressure within the left ventricle; end diastolic pressure (EDP) - the pressure
within the left ventricle at the end of relaxation; (MinP) - the lowest pressure within the
left ventricle; inotropy (dP/dt) - the rate of positive change in pressure with respect to
time; lusitropy (-dP/dt) - the rate of negative change in pressure with respect to time;
one-half relaxation (1/2R) - amount of time from peak tension to 50% of peak tension;
duration of contraction (DCON) - amount of time spent in systole; and duration of
relaxation (DREL) - amount of time spent in diastole. The technique of direct
intraventricular catheterization via the common carotid artery has the advantage of being
able to accurately measure heart functional parameters without the technical
complications and physical trauma of opening the chest cavity.
Baseline data (before the injection of cocaine or vehicle) was recorded for 10 min
in order to establish a control for each animal. The animals were then injected with
either 1 ml sterile isotonic saline (vehicle) or cocaine (2 mg/kg) reconstituted in 1 ml of
sterile isotonic saline. After injection, data was recorded every 10 s for a total of 30 min
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and then exported to an Excel spreadsheet. After data collection, the animal was
euthanized via intravenous injection of saturated potassium chloride (Sigma) in water.
The whole heart was carefully removed and weighed on an analytical mass balance. The
left ventricle was then isolated from the rest of the heart tissue and divided into several
sections for subsequent experiments. All sections were snap-frozen with liquid nitrogen
and stored at -80°C until use.

EXPERIMENTS WITH ECSTASY

Dual-Luciferase Luminometry
In these experiments, we observed the effects of ecstasy on N F - K B activity in
cultured cardiac myocytes. Ecstasy is a schedule I substance with the Drug Enforcement
Agency (DEA) of the United States and was obtained, stored, handled, and disposed of
in accordance with federal, state, and University regulations by a DEA licensed
investigator (Dr. Barbara Y. Hargrave). The same protocol as described in our cocaine
experiments was used to maintain and treat the cells with the exception that on day 3, the
following concentrations of MDMA were tested: 0 M, 1X10"6 M, IX10"5 M, IX10"4 M,
1X1(T M, and 1X10"Z M. The drug was dissolved in enough cell culture media to
achieve each concentration and 2 ml of each dose was gently added to the appropriate
wells. To examine the effects of IKB overexpression on ecstasy induced N F - K B activity,
cells co-transfected with IKB DNA were stimulated with either 0 M, 1X10"3 M, or
1X1 ( T M MDMA. For a summary of the transfection and drug dosage scheme, see
Tables 4 and 5.
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TABLE 4. Transfection Protocol and Drug Dosage Scheme for H9c2
Cells Transfected With N F - K B Reporter and Stimulated With Ecstasy
Well#

1
2
3
4
5
6
7
8
9
10
11
12

Ecstasy
(M)

NF-KB

IKB

pRL-SV40

PCMV

(re)

(re)

(re)

(re)

0
0
1X10"6
1X10"6
1X10"5
1X10"5
1X10"4
1X10"4
1X10"3
1X10"3
IX10"2
1X10"2

1.0
1.0
1.0
1.0
1.0
1.0
1.0
1.0
1.0
1.0
1.0
1.0

0
0
0
0
0
0
0
0
0
0
0
0

0.1
0.1
0.1
0.1
0.1
0.1
0.1
0.1
0.1
0.1
0.1
0.1

1.0
1.0
1.0
1.0
1.0
1.0
1.0
1.0
1.0
1.0
1.0
1.0

TABLE 5. Transfection Protocol and Drug Dosage Scheme for H9c2
Cells Co-Transfected With NF-KB Reporter and IKB Overexpression
Vector and Stimulated With Ecstasy
Well#

1
2
3
4
5
6

Ecstasy
(M)

NF-KB

IKB

pRL-SV40

PCMV

(re)

G*g)

(re)

(re)

0
0
1X10"3
1X10"3
1X10"2
1X10"2

1.0
1.0
1.0
1.0
1.0
1.0

1.0
1.0
1.0
1.0
1.0
1.0

0.1
0.1
0.1
0.1
0.1
0.1

0
0
0
0
0
0

Reactive Oxygen Species Assay
In these experiments, we observed the effects of ecstasy on ROS generation in
cultured cardiac myocytes. The same protocol as described with our cocaine experiments
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was used to maintain and treat the cells with the exception that on day 2, the following
concentrations of MDMA were tested: 1X10"4 M, 1X10"3 M, and 1X10"2 M. The drug
was dissolved in enough Hank's Media to achieve each concentration and 2 ml of each
dose was gently added to the appropriate wells. Just prior to drug exposure, each well
was photographed to obtain a baseline signal. This allowed each well to serve as its own
0 M control. The remainder of the protocol was followed as described in our cocaine
experiments.
Intracellular Calcium Assay
In these experiments, we observed the effects of ecstasy on intracellular Ca2+
levels in cultured cardiac myocytes. The same protocol as described with our cocaine
experiments was used to maintain and treat the cells with the exception that on day 2, the
following concentrations of MDMA were tested: 1X10"4 M, 1X10"3 M, and 1X10"2 M.
The drug was dissolved in enough Hank's Media to achieve each concentration and 2 ml
of each dose was gently added to the appropriate wells. Just prior to drug exposure, each
well was photographed to obtain a baseline signal. This allowed each well to serve as its
own 0 M control. The remainder of the protocol was followed as described in our
cocaine experiments.
Gene Array
In these experiments, we characterized the genetic response of H9c2 cells after
exposure to ecstasy. As in our experiments with cocaine, GEArray™ Q Series Kits
(SuperArray) were used for assessing the transcription levels of certain genes after
exposure to ecstasy. A 96-well array containing genes important to cardiovascular
pathology was used — Mouse Cardiovascular Disease Biomarkers. A different 96-well
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array containing genes important to cardiovascular toxicology was also used — Mouse
Stress & Toxicity Pathway Finder. Some of the genes on the arrays are dependent on
NF-KB

activity.

The same protocol as described with our cocaine experiments was used to
maintain and treat the cells with the exception that on day 1, after becoming
approximately 85% confluent, each T-75 flask was treated with either 0 M or IX10"3 M
MDMA for 24 h. The drug was dissolved in enough cell culture media to achieve each
concentration and 10 ml of each dose was gently added to the appropriate flask. The
remainder of the protocol was followed as described in our cocaine experiments.
Immunohistochemistry
Since our gene array data indicated that MDMA could increase transcription of
certain genes important to inflammation and hypertrophy, the objective of these
experiments was to measure the expression of certain genes on the array at the protein
level within rabbit myocardium after acute MDMA exposure. In situ hybridization
immunohistochemistry allows for localization and quantification of specific proteins in
tissue sections. Specimens collected from our heart function experiment were processed
for the detection of brain natriuretic peptide (BNP), C-reactive protein (CRP), and
troponin 3 (Tnni3). These proteins are important biomarkers for myocardial
inflammation and hypertrophy.
The specimens were fixed in 10% formalin (pH 7.4) (Sigma) for 2 h at 4°C,
followed by 25% sucrose (Sigma) infiltration overnight at 4°C. Next, the tissues were
embedded in Optimal Cutting Temperature Compound (Tissue-Tek) and sectioned at
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5 urn thickness on a cryostat (American Optical) at -20°C. The sections were picked up
on electrostatically treated microscope slides (Fisher) and allowed to air dry for 1 h at
room temperature.
The HistoMark® Biotin Streptavidin-HRP System (Kirkegaard & Perry
Laboratories) was used to stain the sections. All proprietary reagents were obtained from
Kirkegaard & Perry Laboratories unless otherwise indicated. All steps were performed at
room temperature. The slides were rinsed for 15 min in PBS (pH 7.4) and then blocked
for endogenous peroxidase activity by exposure to Universal Blocking Solution for 5
min. After shaking off excess fluid, the slides were exposed to Rabbit Serum Block for
15 min. Primary and secondary antibody solutions were made to a concentration of 10
ug/ml in PBS. For primary antibody exposure, the slides were incubated with Mouse
Anti-Rabbit IgG (Santa Cruz Biotechnology) for 30 min. The primary antibodies were
specific for either BNP, CRP, or TNNI. Afterward, the slides were rinsed in PBS for
5 min. For secondary antibody exposure, the slides were incubated with Biotinylated
Goat Anti-Mouse IgG for 30 min. Next, the slides were rinsed in PBS for 5 min and then
incubated with Streptavidin-Peroxidase Solution for 30 min. After a final rinse in PBS
for 5 min, the slides were exposed to True Blue Substrate for 10 min. The slides were
then rinsed in sterile protease-free water (HyClone) for 2 min, dehydrated on a slide
warmer, and coverslipped with Permount™ mounting medium (Fisher). Target protein
specific staining appeared as light blue colorings within each section. The sections were
digitally photographed under 100X magnification. Images were analyzed by Quantity
One for densitometry.
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Western Blot
As an additional approach to characterizing protein level expression, Western
blots for array-specific proteins were performed. Cultured H9c2 cells treated with
MDMA and myocardial tissues collected from acutely exposed rabbits in our functional
experiments were both processed for this technique. The same protocol as described with
our cocaine experiments was used to maintain and treat the cells with the exception that
on day 1, the following concentrations of MDMA were tested: 0 M, 2 uM, or 1 mM. The
drug was dissolved in enough cell culture media to achieve each concentration and 10 ml
of each dose was gently added to the appropriate flask. Primary antibodies for the
following proteins were used: VCAM-1 or iNOS. Since our ELISA experiments for
NF-KB

indicated the possibility of increased activity at earlier time points and different

concentrations of MDMA, Westerns for VCAM-1 and iNOS were performed at those
corresponding time points and concentrations. For rabbit myocardial tissues from our
functional experiments, primary antibodies for the following proteins were used: BNP
and CRP. The remainder of the protocol was followed as described in our cocaine
experiments.
ELISA
The objective of these experiments was to observe the effects of MDMA on
NF-KB

activity in cultured H9c2 cells and in rabbit myocardium after acute exposure.

Our luminometry experiments revealed that 1 mM MDMA was the minimal dose
required for activating N F - K B in H9c2 cells after 24 h of exposure. Therefore, we
decided to test this particular dose, a maximal dose of 10 mM, and a more clinically
relevant concentration of 2 uM to examine their effects on N F - K B activity at earlier time

46
points of exposure. We also examined rabbit myocardium from acutely treated animals
from our functional experiments.
The H9c2 cells were grown and maintained as described in our luminometry
experiments. On day 1, with the aid of a hemacytometer, approximately 1,000,000 cells
were plated onto each well of a sterile 6-well culture plate (Corning). Enough fresh
media was added to adjust the final volume to 5 ml in each well. The plate was then
returned to the incubator for 24 h. On day 2, the overlying media was removed and
discarded. Each well was treated with either 0 M, 2 uM, 1 mM, or 10 mM MDMA. The
drug was dissolved in enough cell culture media to achieve each concentration and 3 ml
of each dose was gently added to the appropriate wells. The plate was then returned to
the incubator for either 3, 6, or 12 h.
After treatment, the drug solution was removed and discarded. Nuclear proteins
were isolated using a nuclear extraction kit (Panomics). All proprietary reagents were
obtained from Panomics unless otherwise indicated. Working Buffer A for each sample
was made by mixing 1 ml of Buffer A with 10 ul dithiothreitol (DTT), 10 ul Protease
Inhibitor Solution, 10 ul Phosphatase Inhibitor I Solution, and 10 ul Phosphatase
Inhibitor II Solution. Working Buffer B was made by mixing 1 ml of Buffer B with
10 ul DTT, 10 ul Protease Inhibitor Solution, 10 ul Phosphatase Inhibitor I Solution, and
10 ul Phosphatase Inhibitor II Solution. Each well was washed twice with 1 ml of PBS
(pH 7.4). 250 ul working Buffer A was added to each well. The plate was put on ice and
rocked on a platform for 10 min at 200 RPM. Afterward, each well was scraped for 30 s
with a sterile cell scraper and the suspension transferred into separate sterile
microcentrifuge tubes. The tubes were centrifuged at 14,000X for 3 min in a 7°C cold
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room. The supernatant (cytosolic fraction) was removed while the pellet (nuclear
fraction) was placed on ice. 50 ul working Buffer B was added to each tube. The tubes
were vortexed on high for 10 s and then incubated on ice for 1 h with gentle hand
agitation every 20 min. The tubes were then centrifuged at 14,000X for 5 min in a 7°C
cold room. The supernatant (containing nuclear proteins) was transferred into new
separate sterile microcentrifuge tubes and stored at -80°C until use. Protein concentration
for each sample was determined using the Bradford assay.
To isolate nuclear proteins from tissue samples, a slightly different protocol was
followed using the same nuclear extraction kit from Panomics. Working Buffer A and
working Buffer B were made as previously described, but scaled up to accommodate the
volumes needed for tissue processing. All tissue samples were cut into small pieces with
a clean razor blade and 0.5 g was weighed out and place into separate sterile 15 ml
conical tubes. The samples were homogenized on ice in a 7°C cold room. 1.5 ml of
working Buffer A was added to each tube and the contents were again homogenized on
ice in a 7°C cold room. The samples were then incubated on ice for 20 min. Next, the
samples were centrifuged at 850X for 10 min at 4°C. After removal of the supernatant,
1.5 ml of working Buffer A was added to each tube and the contents were homogenized
on ice in a 7°C cold room. The samples were then transferred to separate sterile
microcentrifuge tubes and incubated on ice for 20 min. Afterward, the samples were
centrifuged at 14,000X for 3 min in a 7°C cold room. The supernatant (cytosolic
fraction) was removed while the pellet (nuclear fraction) was placed on ice. 150 ul
working Buffer B was added to each tube. The tubes were vortexed on high for 10 s and
then incubated on ice for 1 h with gentle hand agitation every 20 min. The tubes were
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then centrifuged at 14,000X for 5 min in a 7°C cold room. The supernatant (containing
nuclear proteins) was transferred into new separate sterile microcentrifuge tubes and
stored at -80°C until use. Protein concentration for each sample was determined using
the Bradford assay.
A TransBinding™ N F - K B Assay Kit (Panomics) was used to measure the amount
of N F - K B activity in each sample. This ELISA based method utilizes a special 96-well
Assay Plate coated with N F - K B binding consensus DNA sequence. All proprietary
reagents and plates were obtained from Panomics unless otherwise indicated. An initial
200 ul of Wash Buffer was added to each well and the Assay Plate was incubated for
20 min at room temperature. The wells were then washed 3 times with 200 ul of Wash
Buffer. Next, 40 ul of Binding Buffer was added to each well. Nuclear extracts were
diluted to an equal total protein concentration of 2.0 ug/ul using Nuclear Extract
Dilution Buffer. 10 ul of diluted nuclear extracts were added to the appropriate wells and
the Assay Plate was incubated for 1 h at room temperature with constant agitation on a
rocking platform. The wells were then washed 3 times with 200 ul of Wash Buffer.
Primary antibody specific for N F - K B p50 was diluted 1:100 in Antibody Dilution Buffer.
100 ul of the diluted primary antibody was added to each well and the Assay Plate was
incubated for 1 hour at room temperature with constant agitation on a rocking platform.
The wells were then washed 3 times with 200 ul of Wash Buffer. Next, anti-rabbit
horseradish peroxidase (HRP)-conjugated secondary antibody was diluted 1:1,000 in
Antibody Dilution Buffer. 100 ul of the diluted secondary antibody was added to each
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well and the Assay Plate was incubated for 1 h at room temperature with constant
agitation on a rocking platform. The wells were then washed 3 times with
200 ul of Wash Buffer. Afterward, 100 ul of Substrate Solution was added to each well
and the Assay Plate was wrapped in foil and incubated for 10 min at room temperature.
Finally, 100 ul of Stop Solution was added and the Assay Plate was read within 5 min
for A450 nm on a BMG Fluostar spectrophotometer (BMG Labtechnologies).
In a related set of experiments, we examined the effects of 2 uM and 1 mM
MDMA on N F - K B activity in H9c2 cells at the 15, 30, and 60 min time points. An
updated Transcription Factor ELISA Kit (Panomics) was used for this experiment.
Myocardial tissue samples from our functional experiments and H9c2 cells from our
10 mM MDMA experiments were also analyzed using this kit. Unlike the previous
protocol, this ELISA based method utilizes a separate Sample Plate for the initial mixing
of reagents and a special 96-well Assay Plate coated with streptavidin. A biotinylated
oligonucleotide containing an N F - K B binding consensus DNA sequence is reacted in
solution with samples containing unknown amounts of N F - K B protein. All proprietary
reagents and plates were obtained from Panomics unless otherwise indicated. Binding
Buffer Master Mix was created for each well by combining 10 ul Binding Buffer with
2.5 |al TF-Specific Probe and 27.5 ul sterile nuclease-free water. 40 ul of Binding Buffer
Master Mix was added to each well of the Sample Plate. Nuclear extracts were diluted to
an equal total protein concentration of 2.0 ug/ul using Nuclear Extract Dilution Buffer.
10 ul of diluted nuclear extracts were added to the appropriate wells and the Sample
Plate was incubated for 30 min at room temperature with constant agitation on a rocking
platform. The Assay Plate was prepped to capture TF-DNA complexes by washing 3
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times with 200 ul of Wash Buffer. Afterward, 45 ul of sample solution from each well of
the Sample Plate was added to the corresponding well of the Assay Plate. The Assay
Plate was then incubated for 1 h at room temperature with constant agitation on a
rocking platform. The wells were then washed 3 times with 200
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of Wash Buffer.

Primary antibody specific for N F - K B p50 or p65 was diluted 1:200 in Antibody Dilution
Buffer. 100 ul of the diluted primary antibody was added to each well and the Assay
Plate was incubated for 1 h at room temperature with constant agitation on a rocking
platform. The wells were then washed 3 times with 200 ul of Wash Buffer. Next, antirabbit HRP-conjugated secondary antibody was diluted 1:200 in Antibody Dilution
Buffer. 100 ul of the diluted secondary antibody was added to each well and the Assay
Plate was incubated for 1 h at room temperature with constant agitation on a rocking
platform. The remainder of the protocol was followed as described for the previous kit.
Heart Function
In these experiments, we characterized the functional response of the intact heart
to acute ecstasy exposure. As in our cocaine experiments, the New Zealand White
(NZW) rabbit (Oryctolagus cuniculus) was used for this part of the study. The same
animal care and surgical procedures were followed as described previously. All animals
were maintained by the Animal Care Director and Veterinarian at Old Dominion
University's Department of Biological Sciences housing facility and treated humanely in
accordance with federal regulations (IACUC protocol number 08-011; September 18,
2008).
Baseline data was recorded for 10 min in order to establish a control for each
animal. The animals were then injected with either 1 ml sterile isotonic saline (vehicle)
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or 2 mg/kg ecstasy reconstituted in 1 ml of sterile isotonic saline. To determine if nitric
oxide synthase (NOS) inhibition alters the functional changes induced by ecstasy, some
animals were given 10 mg/kg NG-nitro-L-arginine methyl ester (L-NAME) reconstituted
in 1 ml of sterile isotonic saline for 10 minutes prior to ecstasy exposure. Data was
recorded every 10 seconds for a total of 15 min and then exported to an Excel
spreadsheet. The remainder of the protocol was followed as described in our cocaine
experiments.
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RESULTS

EXPERIMENTS WITH COCAINE

Dual-Luciferase Luminometry
NF-KB

activity is important to many myocardial pathophysiological processes

including inflammation and hypertrophy. The purpose of these experiments was to
observe the effects of cocaine on the N F - K B response in cultured H9c2 cells. This cell
line provides a valuable in vitro model for the study of various drugs on cardiac
myocytes. Drug metabolizing enzymes CYP1A1, CYP1B1, CYP2B1, CYP2B2,
CYP2E1, and CYP2J3 are expressed in both H9c2 and adult rat heart cells.128 Dualluciferase luminometry allows for internal normalization of target gene activity to a
constitutively active reporter gene. The normalized ratiometric data minimizes the
effects of certain subjective errors and allows for a more accurate compilation of data
obtained during different trial runs.
Figure 1 shows that 1X10"3 M and 1X10"2 M cocaine at 24 h significantly
activated N F - K B in cultured H9c2 cells 24 h after exposure and the high dose of
1X10"2 M cocaine significantly activated N F - K B despite the presence of

IKB

overexpression (Figure 2). These results indicate that in cultured cardiac myocytes,
cocaine activates N F - K B in a dose-dependent manner and that

IKB

overexpression is not

sufficient to block this response at the high dose of IX10"2 M cocaine.
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Figure 1. N F - K B activity in H9c2 cells stimulated with cocaine for 24 h. (n = 5
separate experiments). Cells in the 0 M wells were exposed to media only and served as
controls. Data are stated as mean relative luminometry unit (RLU) ratio (experimental
reporter signal/control reporter signal) ± SD. * = p < 0.05 vs. 0 M.
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Figure 2. N F - K B activity in H9c2 cells co-transfected with N F - K B reporter and IKB
overexpression vector and stimulated with cocaine for 24 h. (n = 5 separate
experiments). Cells in the 0 M + IKB wells were exposed to IKB overexpression
vector in media only and served as controls. Data are stated as mean RLU ratio ± SD.
* = p < 0.05 vs. 0 M + IKB.
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Reactive Oxygen Species
Evidence in rats indicates that cocaine can reduce intracellular antioxidant
potential and increase the risk for ROS generation in the myocardium.59'63 ROS can
damage biological macromolecules and cellular structures. ROS are also known to
activate N F - K B . The purpose of these experiments was to observe the effects of cocaine
on ROS generation in cultured cardiac myocytes. We loaded H9c2 cells with the ROS
indicator 2',7'-dichlorofluorescin diacetate and measured ROS generation in response to
cocaine using confocal microscopy. We found that H9c2 cells began to generate
significant amounts of ROS relative to background upon exposure to 1X10"3 M and
1X10" M cocaine, causing a 77% and 69% increase respectively, at 5 min (Table 6).
This finding indicates that cocaine can significantly increase intracellular ROS in
cultured cardiac myocytes, and since ROS can activate N F - K B , it is possible that cocaine
activates N F - K B by increasing the net generation of this free radical.

TABLE 6. Mean Intensity of H9c2 Cells Loaded With 2',7'-Dichlorofluorescin
Diacetate (ROS) Indicator and Stimulated With Cocaine
Drug
Concentration

Control Signal

ROS Signal
2 min post-drug

ROS Signal
5 min post-drug

1X10"4M
1X10"3M
1X10"2M

203.0 ±62.7
364.6 ± 226.3
392.3 ±188.5

222.5 ± 120.4
582.1 ±358.2*
564.0 ± 292.2*

223.6 ±138.4
645.0 ±438.1*
662.3 ± 404.0*

* = p < 0.05 vs. Control Signal, (n = 3).

Cocaine-induced catecholaminergic stimulation is also known to elevate both
intracellular Ca2+ and to increase contractility of the left ventricle.29 To determine if the
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cocaine induced increase in intracellular Ca was associated with ROS generation, we
pre-treated H9c2 cells with either the antioxidant N-acetylcysteine (NAC), or the Ca
channel blockers verapamil, or nifedipine, or the P-adrenergic receptor blocker nadolol,
and then exposed the cells to 1X10" M cocaine. Pre-treatment with 1 mM NAC, blunted
the increase in ROS normally induced by exposure to 1X10" M cocaine, causing a 22%
decrease in the ROS signal at 5 min. Pre-treatment with 10 uM nifedipine also blunted
the increase in ROS normally induced by 1X10" M cocaine at 2 min, however, this
effect was transient and not observed at 5 min. Pre-treatment with either 10 uM
verapamil or 10 uM nadolol did not affect the increase in ROS normally induced by
1X10"2 M cocaine at either 2 min or 5 min. These findings suggest that antioxidant pretreatment is more effective in reducing ROS generation than Ca2+ channel antagonist or
P-adrenergic blockade. Table 7 summarizes the results of these experiments.

TABLE 7. Mean Intensity of H9c2 Cells Loaded With 2',7'-Dichlorofluorescin
Diacetate (ROS) Indicator, Pre-Treated With Various Agents, and Stimulated With
Cocaine
Drug
Concentration

Control Signal

ROS Signal
2 min postcocaine

ROS Signal
5 min postcocaine

lX10"2M+lmMNAC
1X10"2 M + 10 uM verapamil
1X10"2M+ 10 \xM nifedipine
1X10"2M+ 10 uM nadolol

295.8 ±111.0
261.2 ± 140.0
187.3 ±69.9
120.5 ±81.1

No Data
371.0 ± 165.6*
259.6 ±112.8
178.8 ±119.8*

230.8 ±160.7
399.1 ± 143.4*
281.1 ± 105.3*
194.7 ±154.5*

p < 0.05 vs. Control Signal, (n = 3).
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Dual-Luciferase Luminometry With Antioxidant Pre-Treatment
We tested the efficacy of antioxidant pre-treatment in reducing the

NF-KB

response induced by 1X10"2 M cocaine. Since cocaine significantly increased ROS in
our confocal experiments and ROS are implicated in N F - K B activation, we felt that these
experiments were warranted. Figure 3 shows the N F - K B activity in cultured H9c2 cells
exposed to 1X10"2 M cocaine, or pre-treated with the antioxidants glutathione (1 mM)
and/or NAC (1 mM) then exposed to cocaine. While pre-treatment with glutathione
caused a 33% decrease in N F - K B activity, this change was not statistically different from
cells exposed to cocaine alone. However, in cells pre-treated with NAC, then exposed to
cocaine, there was a significant decrease in N F - K B activity compared to cocaine
treatment alone. When cells were pre-treated with both glutathione and NAC, there was
an 83% inhibition of the cocaine induced activation of

NF-KB.

These results indicate that in cultured cardiac myocytes, the ROS generated by
cocaine are responsible for N F - K B activation and that NAC is more effective than
glutathione in reducing this response. These findings are interesting since NAC exerts its
1 9Q

antioxidant effects by acting as a precursor for replenishing glutathione.

One would

therefore expect that pre-treatment with glutathione itself would be more effective in
reducing N F - K B activity compared to pre-treatment with NAC. A possible explanation
for the effectiveness of NAC may be that NAC enters the cell more efficiently than
glutathione due to its lower molecular weight.
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Figure 3. N F - K B activity in H9c2 cells pre-treated with antioxidant for 15 min and
stimulated with cocaine for 6 h. (n = 10 separate experiments). Cells in the 0 M wells
were exposed to media only and served as controls. Data are stated as mean RLU
ratio ± SD. * = p < 0.05 1X10"2 M Coc vs. 0 M Coc and 1X10"2 M Coc + 1 mM Glut vs.
0 M Coc. # = p < 0.05 1X10"2 M Coc + 1 mM NAC vs. 1X10"2 M Coc and 1X10"2 M
Coc + 1 mM Glut + 1 mM NAC vs. 1X10"2 M Coc.

Intracellular Calcium Experiments
z .
In cardiac myocytes, intracellular Ca,2+
^ is an important ion involved with second

messenger signaling and the excitation-contraction mechanism. Ca

overload has been

linked to myocardial apoptosis, hypertrophy, and dysfunction. Our previous studies
suggested that antioxidant pre-treatment, but not Ca channel blocker pre-treatment,
reduced the cocaine induced generation of ROS. The data suggested that the mechanism
of ROS generation by cocaine may not involve the increase in intracellular Ca2+.
However, cocaine is known to increase contractility in the heart which requires elevated
intracellular Ca2+. To determine if cocaine increased intracellular Ca +, we exposed
H9c2 cells to 1X10"5 M, 1X10"4 M, 1X10"3 M, and 1X10"2 M cocaine and measured
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intracellular Ca2+ using the fluorescent Ca2+ indicator fluo-3 and confocal microscopy.
Cocaine at concentrations of 1X10"4 M, IX10"3 M, and 1X10"2 M significantly elevated
intracellular Ca2+ at both 2 and 5 min (Table 8). This finding indicates that cocaine can
significantly elevate intracellular Ca in cultured cardiac myocytes.

TABLE 8. Mean Intensity of H9c2 Cells Loaded With the Intracellular Ca2+
Indicator Fluo-3 and Stimulated With Cocaine
Drug
Concentration

Control Signal

Ca2+ Signal
2 min postcocaine

Ca2+ Signal
5 min postcocaine

1X10~5M
1X10"4M
1X10"3M
1X10"2M

70.2 ± 39.2
92.9 ±50.9
134.1 ±66.9
83.2 ±32.2

75.9 ±27.6
106.6 ±68.2*
219.7 ±185.9*
206.6 ±183.3*

75.1 ±27.5
107.7 ±68.0*
216.5 ±176.5*
600.2 ± 728.7*

* = p < 0.05 vs. Control Signal, (n = 3).

Since the extracellular fluids surrounding cardiac myocytes is an important source
-\\

9-1-

of intracellular Ca by way of voltage-gated Ca channel conductance, and ROS can
damage internal Ca2+ storage compartments causing release of free Ca2+ into the cytosol,
we tested the efficacy of Ca2+ channel blocking and antioxidant pre-treatment on
reducing the cocaine-induced elevation of intracellular Ca

in cultured cardiac

myocytes.
Pre-treatment of H9c2 cells with the Ca channel blockers verapamil (10 uM)
or nifedipine (10 uM) decreased the intracellular Ca2+ levels normally induced by
1X10"4 M cocaine at both 2 and 5 min (Table 9). In the previous experiment (Table 8),
the 1X10"4 M concentration of cocaine caused a 16% increase in intracellular Ca2+ at
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5 min, and the increase was statistically significant over baseline. In this experiment,
using the same concentration of cocaine, 10 uM verapamil pre-treatment followed by
1X10"4 M cocaine led to only a 9% increase of intracellular Ca2+ at 5 min, while 10 uM
nifedipine pre-treatment followed by 1X10"4 M cocaine led to a 4% decrease of
intracellular Ca2+ at 5 min. These changes were statistically no higher or lower than
9+

baseline, implying that Ca

levels remained at baseline despite the presence of

1X10"4M cocaine. Pre-treatment with 10 \xM verapamil had a similar effect by
9+

"3

decreasing the intracellular Ca levels normally induced by 1X10" M cocaine at 2 min,
however, this effect was transient and not maintained to the 5 min mark (Table 9).
94-

Although both compounds block Ca conductance through the L-type Ca

94-

channel in

the heart, the differences in efficacy between verapamil and nifedipine may be attributed
to the different binding sites and binding affinities of each drug for the channel.130'131
9+

In contrast to the Ca channel blockers, pre-treatment with the antioxidant 1 mM
NAC decreased the intracellular Ca2+ levels normally induced by both 1X10"4 M and
1X10" M cocaine at 2 and 5 min (Table 10). Since neither verapamil nor nifedipine
showed this effect at the 1X10' M concentration of cocaine, these results suggest that
increasing cellular antioxidant capacity may be more effective than Ca2+ channel
blockade in protecting against cocaine-induced intracellular Ca2+ elevation in cultured
cardiac myocytes.
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TABLE 9. Mean Intensity of H9c2 Cells Loaded With the Intracellular Ca2+
Indicator Fluo-3, Pre-Treated With Ca2+Channel Blockers, and Stimulated
With Cocaine
Drug
Concentration

Control Signal

Ca2+ Signal
2 min postcocaine

Ca2+ Signal
5 min postcocaine

1X10"4 M + 10 nM verapamil
1X10" 3 M+10 nM verapamil
1X10"2M+ 10 \M verapamil
1X10" 4 M+10 nM nifedipine
1X10" 3 M+10 ^M nifedipine
1X10"2 M + 10 \M nifedipine

116.8 + 48.9
151.3 ±74.5
133.3 ±83.3
99.0 ±63.4
147.1 ±67.7
223.0 ± 179.5

118.1 ±54.8
169.5 ± 86.7
160.0 ±68.6*
94.0 ±55.6
132.5 ± 56.7*
302.1 ± 206.3*

127.4 ±72.2
259.5 ± 134.0*
194.4 ±70.6*
94.8 ±55.8
132.9 ±55.0*
412.7 ± 392.5*

* =p

< 0.05 vs. Control Signal, (n = 3).

TABLE 10. Mean Intensity of H9c2 Cells Loaded With the Intracellular Ca2+
Indicator Fluo-3, Pre-Treated With NAC, and Stimulated With Cocaine
__

Drug
Concentration
1X10" 5 M+1
1X10" 4 M+1
1X10" 3 M+1
1X10" 2 M+1

mMNAC
mMNAC
mMNAC
mMNAC

__

Control Signal

Ca Signal
2 min postcocaine

Ca Signal
5 min postcocaine

140.0 ± 74.0
157.2 ±94.1
201.9 ±131.4
122.4 ±104.1

145.2 ±114.4
147.5 ± 74.3
187.1 ± 107.2
233.3 ±214.2*

149.4 ±73.5
170.1 ±99.6
203.5 ±102.3
440.0 ±440.6*

* = p < 0.05 vs. Control Signal, (n = 3).

Gene Array
Our luminometry and confocal experiments revealed that 1X10" M and 1X10" M
cocaine significantly activates N F - K B , and that 1X10"4 M, IX10"3 M, and 1X10"2 M
cocaine significantly elevates intracellular Ca in cultured cardiac myocytes. Both of
these effects could potentially alter the transcription of genes that are detrimental to
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cardiac homeostasis. Therefore, we characterized the genetic response of cocaine treated
H9c2 cells and the rabbit myocardium exposed to cocaine in vivo using arrays containing
genes associated with cardiovascular disease and toxicity.
Cultured H9c2 cells treated with 1X10"2 M cocaine for 24 h and rabbit left
ventricular heart tissue exposed to cocaine (2 mg/kg) in vivo exhibited alterations in
mRNA expression levels of genes involved with cardiovascular disease and Ca
signaling (Tables 11 and 12). Signal ratios appeared to be stronger in the Ca

signaling

array for rabbit heart tissue compared to the H9c2 cells and in some cases, genes not
activated in H9c2 cells were found to be active in the rabbit heart. For example,
BRCA-1 and Calb2, genes involved with hypertrophy and anti-apoptosis, were both
upregulated in rabbit heart tissue, but not in H9c2 cells. This may be due to differences
in cell type and environment (cardiac myoblasts in vitro vs. adult cardiac myocytes in
vivo), or differences in duration of cocaine exposure (24 h vs. 30 min).
In the cardiovascular disease biomarker array, cocaine upregulated genes
associated with apoptosis, inflammation, heart failure, and cardiac remodeling in H9c2
cells (Table 11). Upregulation of the KCNA5 gene was verified by temperature gradient
RT-PCR (Figure 4). Increased expression of this gene is associated with cardiac
rhythmic abnormalities because potassium channels are important to the repolarization
phase of the cardiac action potential.116 These results indicate that the detrimental effects
of cocaine extend to the genetic level. Cocaine also upregulated pro-survival and growth
suppressive genes, implying that compensatory mechanisms may be activated in
response to the hypoxia caused by vasoconstriction by this drug. For example, if cocaine
causes coronary artery vasoconstriction which leads to decrease flow of blood and

62
decreased nutrient delivery to the myocardium, then elevated expression of hexokinase 2
(HK2) is a compensatory action since this enzyme works to increase the flow of glucose
into cells.132 It is interesting that cocaine increased the expression of N F K B I . This shows
that cocaine both activates N F - K B and increases the amount of the p50 subunit itself so
that more N F - K B can be made, a possible mechanism for amplifying the N F - K B signal.
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TABLE 11. Genes Affected by Cocaine in H9c2 Cells and Rabbit Heart:
Mouse Cardiovascular Disease Biomarkers Array
Additional Information

Gene

Signal Ratio
H9c2 Cells

Signal Ratio
Rabbit Heart

Genes associated with
apoptosis

TNFa (tumor necrosis
factor alpha)
Fas
CD40L
FasL

»10

2.5

1.7
»10
10.7

4.9
4.1
»10

CRLF1 (cytokine
receptor-like factor 1)

6.3

2.6

NFKBI

5.1

6.1

10.7

6.4

11.2

3.2

5.1
2.3

1.5
8.0

»10
14.2

5.4
13.1

»10

8.0

Genes associated with
inflammation

Genes associated with
infarction, heart failure
and cardiac remodeling

(p50)

Timp (matrix
metalloproteinase
inhibitor)
PPARy (peroxisome
proliferator-activated
receptor gamma)
Tnni3 (troponin I type 3)
ANP (atrial natriuretic
peptide)
CRP (c-reactive protein)
BNP (brain natriuretic
peptide)
iNOS (inducible nitric
oxide synthase)

Genes from the Mouse Cardiovascular Disease Biomarkers array.
Signal ratio = [(target geneexp-blankeXp)/(GAPDHexp-blankeXp)]/[(target genecontroiblankcontroO^GAPDHcontroi-blankcontroi)]- » 1 0 = a large positive response with a low
control signal.
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TABLE 12. Genes Affected by Cocaine in H9c2 Cells and Rabbit Heart:
Mouse cAMP/Ca2+ Signaling Pathway Finder Array
Additional Information

Gene

Signal Ratio
H9c2 Cells

Signal Ratio
Rabbit Heart

Genes associated with
cardiac hypertrophy

Adrbl (beta 1 adrenergic
receptor)
AHR (ary 1-hydrocarbon
receptor)
ANG (angiotensinogen)
BRCA-1 (breast cancer 1
protein)
Ode (ornithine
decarboxylase)

2.0

6.1

1.7

3.5

1.6
1.7

2.9
4.0

1.1

3.8

Genes associated with
growth suppression

SMST (somatostatin)
SSTR2 (somatostatin
receptor subtype 2)

2.0
2.2

10.4
8.1

Genes associated with
anti-apoptosis

Calbl (calbindin 1)
Calb2 (calbindin 2)

2.3
1.3

2.0
»10

Genes associated with
heart failure

CRH (corticotropin
releasing hormone)
KCNA5 (voltage-gated
potassium channel, shakerrelated subfamily 5

0.9

3.1

2.3

8.4

Gene associated with
glucose metabolism

HK2 (hexokinase 2)

1.9

»10

Gene associated with
apoptosis

TNFa (tumor necrosis
factor alpha)

1.3

3.0

Genes from the Mouse cAMP/Ca Signaling Pathway Finder array.
Signal ratio = [(target geneexp-blankexp)/(GAPDHexp-blankexp)]/[(target genecontroiblankcontroi)/(GAPDHcontroi-blankcontroi)]- » 1 0 = a large positive response with a low
control signal.
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Figure 4. Temperature gradient RT-PCR for KCNA5 gene rabbit heart. Lane 4 optimal
annealing temperature 59.1°C. KCNA5 signal was normalized to GAPDH
(housekeeping gene) signal. Semi-quantitative densitometry analysis indicated that
KCNA5 mRNA was increased in the cocaine group compared to the placebo group. Left
= placebo. Right = cocaine.

Western Blot
The previously described gene array experiments (Tables 11 and 12) indicated that
the mRNA transcript levels of certain genes are affected by cocaine. Therefore, the
purpose of the next experiments was to measure the protein level expression of arrayspecific genes in cocaine treated cardiac myocytes. BNP, CRP, and Tnni3 are known to
be upregulated during heart failure. These genes were also upregulated in the array
experiments. We therefore performed Western blots for these proteins in cultured H9c2
cells exposed to 1X10"2 M cocaine for 24 h. The results indicated that there were no
significant differences in BNP, CRP, or Tnni3 expression compared to 0 M control.
Immunoreactive bands did not resolve near the appropriate molecular weight markers for
any of these proteins. These results suggest that cocaine does not affect the expression of
these genes at the protein level. It is also possible that technical difficulties, including the

lack of a positive control and the lack of quality controlled antibodies, may have
contributed to the lack of useful data in this assay. For a sample Western blot for BNP,
see Figure 5.
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Figure 5. Representative example of Western blot for BNP (36 kDa) after 1X10" M
cocaine treatment for 24 h. Colorimetric molecular weight markers in lane 1
superimposed upon chemiluminescent reactions in remainder of membrane.
Lane 2 = empty. Lanes 3, 5, and 7 = 0 M cocaine. Lanes 4, 6, and 8=1X10" 2 M cocaine.
Bracketed lanes are paired to each other. V = 0 M cocaine treated (cells
treated with media only). C = 1X10" M cocaine treated. Unknown bands with
strong immunoreactivity present near 160 kDa marker.

Heart Function
The purpose of these experiments was to characterize the functional response of
the intact heart to acute cocaine exposure in vivo. The New Zealand White (NZW) rabbit
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{Oryctolagus cuniculus) was used for these studies. Rabbits have been used extensively
in studies designed to assess the impact of illicit drugs on the heart.133"135 The functional
and anatomical features of the heart from this species are very similar to other mammals,
including humans, making it ideal for our studies.
With the animal under a surgical plane of anesthesia, cocaine was given as an
intravenous bolus (2 mg/kg) and left ventricular function assessed. Acute exposure to
cocaine significantly decreased heart rate at 15 min; dP/dt at 1 min; and -dP/dt at 5, 15,
and 30 min relative to baseline control. The decrease in -dP/dt (lusitropy) was the only
parameter sustained until the end of the experiment. Lusitropy is the rate of relaxation
and is normally increased in response to sympathetic stimulation to allow for efficient
ventricular filling of blood between contractions. A decrease in lusitropy is abnormal for
a drug that is supposed to act as a sympathomimetic. In addition, cocaine significantly
increased DREL at 15 min, however this was not sustained. These results suggest that in
the intact rabbit, cocaine depresses overall cardiac function. This may be related to the
ability of cocaine to increase ROS which may disrupt mitochondrial function and ATP
production. Less ATP means less energy available to power myocardial contraction.
With the exception of-dP/dt, all other functional parameters that were
significantly altered by cocaine (HR, dP/dt, and DREL) returned to baseline before
30 min. This may be due to the diminishing concentration of cocaine over time due to
enzymatic metabolism and urinary elimination. The estimated half-life of cocaine
(45 - 90 min) is very close to the end of the experimental time point. Table 13
summarizes left ventricular functional findings in the rabbit acutely exposed to 2 mg/kg
cocaine.
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TABLE 13. Left Ventricular Function in NZW Rabbits Acutely Given
Cocaine (2 mg/kg)
Time

HR

MaxP

EDP

dP/dt

-dP/dt

(beats/min)

(mm Hg)

(mm Hg) (mm Hg/s)

(mm Hg/s)

Before Cocaine

218 ±20

70 ± 1

56 ± 2

1154+ 108

689+108

lmin
After Cocaine
5min
After Cocaine

206 + 28

66 + 4

52 + 6

923 + 173*

637+143

215 + 22

72 + 4

60 + 4

1106+178

644+120*

15min
After Cocaine

208 + 22*

71+4

57 + 3

1121+200

645+122*

30min
After Cocaine

213 + 28

71+6

58 + 5

1126+165

618+106*

Data are stated as mean ± SD. (n = 4). HR = heart rate in beats/min.
MaxP = maximum systolic pressure in mm Hg. EDP = end diastolic pressure in mm Hg.
dP/dt = maximum rate of positive change in pressure (inotropy) in mm Hg/s.
-dP/dt = maximum rate of negative change in pressure (lusitropy) in mm Hg/s.
* = p < 0.05 vs. Before Cocaine.

EXPERIMENTS WITH ECSTASY

Dual-Luciferase Luminometry
NF-KB

activity is important to many myocardial pathophysiological processes

including inflammation and hypertrophy. The purpose of these experiments was to
observe the effects of ecstasy on the N F - K B response in cultured cardiac myocytes.
We observed that 1X10"3 M and 1X10"2 M MDMA at 24 h significantly activated

NF-KB

in cultured H9c2 cells (Figure 6). IKB overexpression was able to significantly reduce
the MDMA induced N F - K B response in the IKB + 1X10"3 M group, but not the IKB +
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1X10" M group (Figure 7). These results indicate that in cultured cardiac myocytes,
MDMA activates N F - K B in a dose-dependent manner and that IkB overexpression is
sufficient to block this response at 1X10"3 M MDMA, but not at the high dose of
1X10"2MMDMA.

Figure 6. N F - K B activity in H9c2 cells stimulated with ecstasy for 24 h. (n = 3 separate
experiments). Cells in the 0 M wells were exposed to media only and served as controls.
Data are stated as mean RLU ratio ± SD. * = p < 0.05 vs. 0 M.
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Figure 7. N F - K B activity in H9c2 cells co-transfected with N F - K B reporter and
IKB overexpression vector and stimulated with ecstasy for 24 h. (n = 3 separate
experiments). Cells in the 0 M + IKB wells were exposed to IKB overexpression
vector in media only and served as controls. Data are stated as mean RLU ratio ± SD.
* = p < 0.05 vs. 0 M + IKB.

Reactive Oxygen Species
ROS can damage biological macromolecules and cellular structure. ROS are also
known to activate N F - K B . The purpose of these experiments was to observe the effects
of ecstasy on ROS generation in cultured cardiac myocytes. H9c2 cells exposed to
1X10"4 M or 1X10"3 M MDMA did not significantly affect ROS generation at any of the
time points tested. However, exposure to 1X10" M MDMA caused a significant increase
in ROS after 5 min (Table 14). This indicates that in cultured cardiac myocytes, a
relatively high concentration of MDMA is required to induce significant ROS generation
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above background. However, it is unknown if the lower concentrations may increase
ROS generation at later time points (ie. beyond 5 min).

TABLE 14. Mean Intensity of H9c2 Cells Loaded With 2',7'-Dichlorofluorescin
Diacetate (ROS) Indicator and Stimulated With Ecstasy
Drug
Concentration

Control Signal

ROS Signal
2 min postecstasy

ROS Signal
5 min postecstasy

1X10"4M
1X10"3 M
1X10"2M

547.1 ± 102.5
595.8 + 55.3
654.1 ±75.7

573.5 ±109.8
611.7 ±50.2
717.6 ±83.6

595.5 ±110.8
660.6 ± 68.8
782.1 ±80.4*

* = p < 0.05 vs. Control Signal, (n = 3).

Intracellular Calcium Experiments
In cardiac myocytes, intracellular Ca2+ is an important ion involved with second
messenger signaling and the excitation-contraction mechanism. Ca

overload has been

linked to myocardial apoptosis, hypertrophy, and dysfunction. The purpose of these
experiments was to observe the effects of ecstasy on intracellular Ca2+ levels in cultured
cardiac myocytes. H9c2 cells exposed to 1X10"4 M MDMA did not show a significant
increase in intracellular Ca2+. However, exposure to 1X10"3 M and 1X10"2 M MDMA
significantly increased intracellular Ca2+ at both the 2 and 5 min time points (Table 15).
These results indicate that in cultured cardiac myocytes, MDMA can significantly
elevate intracellular Ca +. In addition, since MDMA elevates intracellular Ca + at
concentrations less than what is required for significant ROS generation, ROS may not
play a role in Ca release from internal stores.
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TABLE 15. Mean Intensity of H9c2 Cells Loaded With the Intracellular Ca
Indicator Fluo-3 and Stimulated With Ecstasy
Drug
Concentration

Control Signal

Ca2+ Signal
2 min postecstasy

Ca2+ Signal
5 min postecstasy

1X10"4M
1X10"3 M
1X10"2M

299.1 ±96.6
207.1 ±118.7
139.1 ±62.3

284.2 ±96.1
247.3 ±121.2*
301.3 ±205.9*

311.9+ 115.0
254.0 ±145.0*
320.9 ± 287.9*

* = p < 0.05 vs. Control Signal, (n = 3).

Gene Array
The luminometry and confocal experiments revealed that ecstasy, at certain
concentrations, can significantly activate N F - K B and elevate intracellular Ca in
cultured cardiac myocytes. This could potentially alter the transcription of genes that are
detrimental to cardiac homeostasis. Therefore, the purpose of these experiments was to
characterize the genetic response of ecstasy treated H9c2 cells using arrays containing
genes associated with cardiovascular disease and toxicity.
Cultured H9c2 cells treated with 1X10"3 M ecstasy for 24 h exhibited alterations in
mRNA expression levels of some genes on each array (Tables 16 and 17). Ecstasy
upregulated genes associated with inflammation, hypertrophy, and coronary heart
disease (Table 16). Upregulation of the Tnni3 gene was verified by temperature gradient
RT-PCR (Figure 8). Increased expression of this gene is associated with myocardial
hypertrophy. These results indicate that the detrimental effects of ecstasy extend to the
genetic level. However, ecstasy also upregulated DNA repair, stress response, and pro-
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survival genes while simultaneously downregulating pro-apoptotic genes (Table 17),
showing that, like cocaine, a compensatory response may be activated by this drug.

TABLE 16. Genes Affected by Ecstasy in H9c2 Cells: Mouse Cardiovascular
Disease Biomarkers Array
Additional Information

Gene

Signal Ratio

Gene associated with
coronary heart disease

Apoc2 (Apolipoprotein C-II)

7.12

Genes associated with
inflammation

MCP-1 (monocyte
chemoattractant protein 1)
VCAM-1 (vascular cell
adhesion molecule 1)

8.47

Genes associated with
cardiac remodeling

Gene associated with
cardiac hypertrophy

12.13

Gelatinase A
PLAUR (plasminogen
activator urokinase receptor)
Timp (matrix
metalloproteinase inhibitor)

0.05
7.70

Tnni3 (troponin I type 3)

6.12

0.41

Genes from the Mouse Cardiovascular Disease Biomarkers array.
Signal ratio = [(target geneexp-blankexp)/(GAPDHexp-blankeXp)]/[(target genecontroiblankControi)/(GAPDHControi-blankCOntroi)]- » 1 0 = a large positive response with a low
control signal.
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TABLE 17. Genes Affected by Ecstasy in H9c2 Cells: Mouse Stress &
Toxicity Pathway Finder Array
Additional Information

Gene

Signal Ratio

Genes associated with
apoptosis

caspase-1
caspase-8
FasL
p53

0.41
0.13
0.23
0.33

Genes associated with
cardiac hypertrophy

cyclinDl
cyclin G
PCNA (proliferating cell
nuclear antigen)

3.25
6.77
8.89

Genes associated with
stress response and
pro-survival

cryab (alpha B-crystallin)
hsp2 5 (heat shock protein 25)
hsp60 (heat shock protein 60)
hspa4 (heat shock protein a4)
hspa9 (heat shock protein a9)

2.07
3.55
2.87
4.27
2.43

Genes associated with
DNA repair

Gadd45
RAD23A

2.41
5.27

Genes associated with
inflammation

Cox-2 (cyclooxygenase-2)
MIP-lb (macrophage
inflammatory protein-1 beta)

4.29
2.13

Genes from the Mouse Stress & Toxicity Pathway Finder array.
Signal ratio = [(target geneexp-blankeXp)/(GAPDHexp-blankexp)]/[(target genecontroiblankCOntroi)/(GAPDHControi-blankCOntroi)]- » 1 0 = a large positive response with a low
control signal.

75

1 2 3 4 5 6 7 8

1 2 3 4 5 6 7 8

Tnni3-—______
GAPDH-

""

^___.—-—Tnni3
| |
I

I

Placebo

^ ^ ^ ^ ~ T ^ ~ GAPDH
I

I

MDMA

Figure 8. Temperature gradient RT-PCR for Tnni3 gene H9c2 cells. Lane 4 optimal
annealing temperature 59.1°C. Tnni3 gene was normalized to GAPDH (housekeeping
gene) signal. Semi-quantitative densitometry analysis indicated that Tnni3 mRNA was
increased in the MDMA group compared to the placebo group. Left = placebo. Right =
MDMA.

Immunohistochemistry
The gene array experiments in which H9c2 cells were exposed to ecstasy indicated
that the mRNA transcript levels of certain genes are affected by ecstasy. Therefore, the
purpose of these experiments was to measure the protein level expression of arrayspecific genes in ecstasy treated heart tissues from our functional experiments. The
expression of Tnni3 was analyzed in these experiments. This gene is known to be
upregulated during cardiac hypertrophy. The expression of BNP and CRP were also
analyzed. Both BNP and CRP are upregulated during heart failure. Although the
antibody specific stain for Tnni3 revealed the presence of this protein in both placebo
and MDMA treated heart tissues, densitometry analysis of rabbit myocardium acutely
exposed to 2 mg/kg MDMA for 15 min did not reveal any significant difference in the
amount of Tnni3 expression compared to placebo. In addition, no significant differences
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were found in the other proteins analyzed (BNP and CRP). These data suggests that
MDMA does not affect the expression of these genes at the protein level and may be due
to the short duration of exposure to drug given as an intravenous bolus (15 min).
Western Blot
The gene array experiments indicated that the mRNA transcript levels of certain
genes are affected by ecstasy. Therefore, the purpose of these experiments was to
measure the protein level expression of array-specific genes in ecstasy treated cardiac
myocytes. VCAM-1 and iNOS are known to be upregulated during myocardial
inflammation. VCAM-1 was also upregulated in our array experiments. Although iNOS
was not upregulated on the array, we nevertheless decided to test for the expression of
this protein because it is known to be N F - K B dependent. We performed Western blot
analysis for these proteins in cultured H9c2 cells exposed to either 2 uM or 1 mM
ecstasy for 3, 6, or 12 h. These concentrations and time points were chosen because they
corresponded with the same concentrations and time points of significant

NF-KB

activity

in our ELISA experiments.
We saw no significant difference in VCAM-1 or iNOS expression compared to
0 M control. Immunoreactive bands either did not resolve near the appropriate molecular
weight markers, or did not resolve at all for either protein. These results suggest that
ecstasy does not affect the expression of these genes at the protein level. However, it is
possible that these time points are too early for a significant amount of detectable protein
expression to occur. It is also possible that technical difficulties, including the lack of a
positive control and the lack of quality controlled antibodies, may have contributed to
the lack of useful data in this assay. For a sample Western blot for iNOS, see Figure 9.
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Figure 9. Representative example of Western blot for iNOS (130 kDa) after 1 mM
ecstasy treatment for 6 h. Colorimetric molecular weight markers in lane 1 superimposed
upon chemiluminescent reactions in remainder of membrane.
< = iNOS positive control in lane 8. Lanes 2, 4, and 6 = 0 M ecstasy. Lanes 3, 5,
and 7 = 1 mM ecstasy. Bracketed lanes are paired to each other. V = 0 M ecstasy
treated (media only). E = 1 mM ecstasy treated.

ELISA
Our luminometry assay revealed that ecstasy activates N F - K B in cultured cardiac
myocytes after 24 h of exposure. Since it was possible that ecstasy may activate

NF-KB

at earlier time points, we performed a series of experiments to test drug exposure
durations of 3, 6, and 12 h. Enzyme-linked immunosorbent assay (ELISA) provides an
alternative and rapid method for detecting N F - K B activity in ecstasy treated cardiac
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myocytes. We tested 2 [iM MDMA because this concentration is close to that in the
plasma of actual users of this drug. We tested 1 mM MDMA because this concentration
was the minimum capable of activating N F - K B in our luminometry experiments. We
tested 10 mM MDMA because this was the highest concentration capable of activating
NF-KB

in our luminometry experiments.

We observed significant N F - K B p50 activity in H9c2 cells exposed to 2 uM
MDMA at the 12 h time point and 1 mM MDMA at the 6 h time point (Figures 10 and
11). However, we did not observe significant N F - K B p50 activity in H9c2 cells exposed
to 10 mM MDMA for any of the time points tested (Figure 12). These findings, with the
exception of the 10 mM MDMA group, indicate that MDMA activates N F - K B in
cultured cardiac myocytes at time points significantly less than 24 h.

0.35
0.3
0.25

• 0lMIVDIvV\

0.2

0 2L^/l^/DM^
0.15

• Positive Control

0.1
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0

I
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^
6h
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Figure 10. ELISA for N F - K B p50 activity in H9c2 cells stimulated with 2 uM
ecstasy for 3, 6, or 12 h. (n = 3 separate experiments). Cells in the 0 uM wells were
exposed to media only and served as controls. Data are stated as mean A450 ± SD.
* = p < 0.05 vs. 0 \M.
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• OmMIVOVA
0 1 mMIVOVA
D Positive Control

Figure 11. ELISA for N F - K B p50 activity in H9c2 cells stimulated with 1 mM
ecstasy for 3, 6, or 12 h. (n = 3 separate experiments). Cells in the 0 mM wells were
exposed to media only and served as controls. Data are stated as mean A450 ± SD.
* = p < 0.05 vs. 0 mM.
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Figure 12. ELISA for N F - K B p50 activity in H9c2 cells stimulated with 10 mM
ecstasy for 3, 6, or 12 h. (n = 3 separate experiments). Cells in the 0 mM wells were
exposed to media only and served as controls. Data are stated as mean A450 ± SD.
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Since it remained possible that ecstasy could activate N F - K B at time points earlier
than 3 h, we performed another series of experiments involving drug exposure durations
of 15, 30, and 60 min. We did not observe significant

NF-KB

p65 activity in H9c2 cells

exposed to 2 uM or 1 mM MDMA at either the 15, 30, or 60 min time points (Figure
13). Similarly, we did not observe significant

NF-KB

p50 activity in rabbit myocardium

acutely exposed to MDMA from our functional experiments (Figure 14). These results
suggest that these time points of exposure may be too early for significant nuclear
accumulation of

NF-KB.
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Figure 13. ELISA for N F - K B p65 activity in H9c2 cells stimulated with 2 uM or 1 mM
ecstasy for 15, 30, or 60 min. (n = 3 separate experiments). Cells in the 0 uM wells were
exposed to media only and served as controls. Data are stated as mean A450 ± SD.
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Figure 14. ELISA for N F - K B p50 activity in rabbit myocardium stimulated with
2 mg/kg ecstasy for 15 min. (n = 3 separate experiments). Placebo animals were exposed
to 0.9% saline only and served as controls. Data are stated as mean
A450 + SD.

Heart Function
The purpose of these experiments was to characterize the functional response of
the intact heart to acute ecstasy exposure. The same animal model and measuring
techniques were used as in our cocaine experiments. Acute exposure to ecstasy
significantly increased heart rate at all time points, EDP at 5 min, and MinP at 5 min
relative to baseline control. After an initial drop at 1 min, ecstasy also significantly
increased dP/dt at 5 min. Ecstasy significantly decreased -dP/dt at 1 min and DREL at 5
and 15 min. These results suggest that in the intact rabbit, ecstasy acutely increases
cardiac stress by increasing heart rate and contractility. The early decrease in lusitropy
prevents the heart from efficiently relaxing between contractions which reduces
efficiency of ventricular chamber filling between contractions. However, this effect was
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short-lived and followed by an increase in dP/dt which suggests a compensatory increase
in contractility to counteract the reduced cardiac output cause by inefficient chamber
filling. The elevation of EDP at the same time period of 1) increased dP/dt and 2) lack of
significant increase in MaxP, suggests a type of diastolic failure where EDP remains
elevated not because of increased blood volume loading, but because of decreased ability
to fully relax. Table 18 summarizes the left ventricular functional findings in the rabbit
acutely exposed to 2 mg/kg ecstasy.

TABLE 18. Left Ventricular Function in NZW Rabbits Acutely Given
Ecstasy (2 mg/kg)
Time

HR

MaxP

EDP

(beats/min)

(mm Hg)

(mm Hg) (mm Hg/s)

(mm Hg/s)

Before MDMA

191 ± 12

31 ± 3

24 ± 2

503 ± 88

276 ±61

lmin
After MDMA
5min
After MDMA

218 ±22*

32 ± 8

26 ± 9

363 ± 105*

227 ± 72*

226 ±23*

40 ±13

33 ± 1 1 * 570 ± 9 1 *

290 ±83

222 + 30*

36 ±11

28 ± 9

280 ±57

15min
After MDMA

dP/dt

591 ±99

-dP/dt

Data are stated as mean ± SD. (n = 7). HR = heart rate in beats/min.
MaxP = maximum systolic pressure in mm Hg. EDP = end diastolic pressure in mm Hg.
dP/dt = maximum rate of positive change in pressure (inotropy) in mm Hg/s.
-dP/dt = maximum rate of negative change in pressure (lusitropy) in mm Hg/s.
* = p < 0.05 vs. Before MDMA.

Atherosclerosis is a widespread disease condition of fatty substance accumulation,
inflammation, and remodeling of the vascular wall. During atherosclerosis, the
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endothelium is lesioned and this causes a decrease in nitric oxide synthase (NOS)
activity. NOS generated nitric oxide (NO) is known to have beneficial effects on
cardiovascular function including anti-platelet adhesion, vasodilation, and reduction of
myocardial inotropy. It is not uncommon for people with this condition to use illicit
drugs including ecstasy. Therefore, in a related set of functional experiments, the ability
of ecstasy to alter heart function in the presence of NOS inhibition was measured. A
baseline functional reading was recorded for 10 min prior to the delivery of any
substance. Then, the NOS inhibitor L-NAME was injected intravenously and another
functional baseline was recorded for 10 min. Finally, MDMA was injected intravenously
and left ventricular function analyzed.
We observed that pre-treatment with L-NAME alone significantly decreased heart
rate, but significantly elevated MaxP, EDP, MinP, 1/2R, and DREL (Figures 15 and 16).
MDMA exposure after L-NAME pre-treatment significantly decreased heart rate at 1
and 5 min, but significantly elevated MaxP, EDP, and MinP at all time points. DREL
was also significantly elevated at 15 min. See table 19 for a summary of our findings.
MDMA exposure after L-NAME pre-treatment significantly increased DCON at the 1
min mark, an aberration that was not caused by MDMA alone or L-NAME pre-treatment
alone. In addition, the abnormalities in EDP and MinP caused by MDMA alone or LNAME alone were exacerbated by the combination of the two substance. These findings
suggest that L-NAME and MDMA are synergistically detrimental to heart function.
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Figure 15. Effects of L-NAME pre-treatment alone on left ventricular function in NZW
rabbits: HR, dP/dt, -dP/dt, Vi R, DREL. (n = 4 separate experiments). HR = heart rate in
beats per min. dP/dt = maximum rate of positive change in pressure (inotropy) in mm
Hg/s. -dP/dt = maximum rate of negative change in pressure (lusitropy) in mm Hg/s.
1/2R = duration of one-half relaxation in ms. DREL = duration of relaxation in ms. Data
are stated as mean ± SD. * = p < 0.05.
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Figure 16. Effects of L-NAME pre-treatment alone on left ventricular function in NZW
rabbits: MaxP, EDP, MinP, DCON. (n = 4 separate experiments). MaxP = maximum
systolic pressure in mm Hg. EDP = end diastolic pressure in mm Hg. MinP = minimum
diastolic pressure in mm Hg. DCON = duration of contraction in ms. Data are stated as
mean±SD. * = p < 0 . 0 5 .
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TABLE 19. Left Ventricular Function in NZW Rabbits Pre-Treated With
L-NAME (10 mg/kg) for 10 min and Acutely Given Ecstasy (2 mg/kg)
Time

HR
(beats/min)

MaxP
(mm Hg)

EDP
dP/dt
(mm Hg) (mm Hg/s)

-dP/dt
(mm Hg/s)

Before L-NAME

173 + 14

21 ± 4

14 ± 3

442+110

217185

408 ± 143

121 ± 8

L-NAME INJECTION
10 min
After L-NAME

104+10*

27 ± 5 *

19 ± 3 *

MDMA INJECTION
lmin
After MDMA

118 ±13*

51 ±4*

33 ± 3 *

459 ± 94

174 ±19

5 min
After MDMA

138 ±18

39 ± 3*

28 ± 3 *

499 ±154

159 ±29

15 min
After MDMA

122 ±14*

32 ± 3 *

23 ± 2 *

466+149

142 ±29

Data are stated as mean ± SD. (n = 4). HR = heart rate in beats/min.
MaxP = maximum systolic pressure in mm Hg. EDP = end diastolic pressure in mm Hg.
dP/dt = maximum rate of positive change in pressure (inotropy) in mm Hg/s.
-dP/dt = maximum rate of negative change in pressure (lusitropy) in mm Hg/s.
* = p < 0.05 vs. Before L-NAME.
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DISCUSSION AND CONCLUSION

Cocaine and MDMA are among the most commonly used illicit drugs and their
effects on the heart have not been fully characterized. The current study involved several
independently performed experiments designed to expand our understanding about how
these drugs affect the heart at a cellular and intact organ system level. The present results
indicate that cocaine and MDMA are detrimental to multiple parameters of myocardial
homeostasis and that some pre-treatment strategies may have significant prophylactic
potential.
NF-KB

is a critical transcription factor at the center of the inflammatory and

hypertrophic response of the heart. Cocaine and MDMA activated N F - K B in a dosedependent manner. To the best of our knowledge, this is the first time that either cocaine
or MDMA has been shown to activate N F - K B in cultured cardiac myocytes. This finding
helps to explain some of the observations made by previous investigators, whereby the
administration of cocaine or MDMA significantly enhanced leukocyte infiltration into
the myocardium.59'63'67 Activation of N F - K B by these drugs provides a mechanism by
which this inflammatory response may happen.
Since MDMA activated
MDMA-induced

NF-KB

NF-KB

at 24 h, we decided to explore the possibility of

activation at time points of exposure considerably less than

24 h. Using an ELISA protocol, we found that 1.0 mM MDMA significantly activated
NF-KB

in cultured cardiac myocytes at 6 h. This concentration was the minimal amount

capable of activating N F - K B . At 12 h, 2.0 uM MDMA significantly activated

NF-KB.

This concentration is within the range of peak plasma levels seen in actual users of this
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drug. It is interesting that N F - K B was not activated at or before 3 h with either
concentration. It is possible that under the current experimental conditions this amount
of time is not sufficient for significant nuclear accumulation of this transcription factor.
It is also possible that a significant amount of N F - K B activity could be occurring within
the time period just before our earliest assay point (15 min).
A biphasic response to 1.0 mM MDMA is suggested since sometime after 6 h,
NF-KB

activity becomes significantly degraded (no significant activity at 12 h), but then

reappears at 24 h according to our luminometry experiments. It is uncertain why MDMA
is associated with such a temporal response with regard to N F - K B . It is possible that
some metabolic by-product of MDMA may be participating later in the N F - K B response
and/or cellular adaptation is occurring in response to the persistent presence of the drug
and its metabolites over time.
We also tested 10 mM MDMA, the only other concentration that significantly
activated N F - K B . We expected a strong and early activation of N F - K B at this high
concentration. However, we did not observe a significant response at any of the time
points tested. It is unclear why this result occurred. One possibility may be issues
regarding the sensitivities of the different assays. If luminometry is more sensitive than
ELISA, as it has been suggested, then perhaps the latter assay may not be able to resolve
a very slight difference between treatment groups even though one may exist. In order to
confirm this theory, additional experiments with MDMA at the same concentrations and
exposure time points would have to be performed and then analyzed using luminometry.
Another possibility involves alternative N F - K B dimers. There are 15 possible dimer
combinations that can be made from p50, p52, p65, cRel, and RelB proteins. Of these,
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9 are known to have transcriptional activity.136 One theory states that the cellular
repertoire of N F - K B dimers can be altered in response to certain stimuli.

If this

repertoire should change in response to very high concentrations of ecstasy, then one set
of N F - K B dimers containing p50 may be involved with the ELISA signaling seen with
2 uM MDMA and 1 mM MDMA, while another set of N F - K B dimers without p50 may
be involved with the luminometry signaling seen with 10 mM MDMA. This would help
explain the lack of p50 signaling in the ELISA assay at this high concentration.
Both cocaine and MDMA have been shown to reduce the amount of intracellular
glutathione, a major antioxidant. Therefore, it is possible that exposure to either of these
drugs may cause perturbations in redox balance, which may lead to a net increase in
reactive oxygen species (ROS) generation. These free-radicals are known for their direct
deleterious effects on the heart, and also as activators of myocardial

NF-KB.

In order to

explore the possibility of ROS involvement in the cocaine and MDMA induced
activation of N F - K B , fluorescence based confocal microscopy was used to measure the
relative amounts of ROS generated in cultured cardiac myocytes after exposure to each
drug. Within a few minutes, both drugs caused a significant increase in the appearance
of ROS above background. For MDMA, the minimal concentration and time required to
induce this response was 1X10" M at 5 min, and for cocaine, a minimum of 1X10" M at
2 min was required. These findings suggest that under our experimental conditions,
cocaine is more potent than MDMA in generating ROS and that these free radicals may
be responsible for the ability of these drugs to activate

NF-KB.

Since a significant amount of ROS was generated upon exposure to cocaine, and
ROS are known to activate N F - K B , we were interested in observing the effects of
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antioxidant pre-treatment on cocaine induced ROS generation and N F - K B activity in
cultured cardiac myocytes. In addition, because cocaine induced catecholaminergic
stimulation is known to elevate both intracellular Ca2+ and ROS, we also tested the
efficacy of Ca

channel blocking and P-adrenergic receptor blocking pre-treatment to

reduce cocaine induced ROS.
We found that pre-treatment with 1 mM N-acetyl-L-cysteine (NAC) or 10 uM
nifedipine significantly reduced the amount ROS normally generated by 1X10" M
cocaine. However, this effect was not sustained by nifedipine. In addition, pre-treatment
with 1 mM NAC or the combination of 1 mM NAC + 1 mM glutathione significantly
'y

suppressed the N F - K B reporter activity normally induced by 1X10" M cocaine. Pretreatment with 1 mM glutathione also tended to suppress N F - K B reporter activity,
however, the data for this group did not reach statistical significance. Apparently, the
extra free radical buffering capacity offered by antioxidant (1 mM NAC) pre-treatment
was sufficient in quenching enough of the ROS generated by cocaine to attenuate the
NF-KB

response. These observations support the assertion that cocaine induced ROS

generation is responsible for the ability of this drug to activate N F - K B in cultured cardiac
myocytes.
Ca2+ is an important ion that acts as both as a second-messenger and as a direct
effector in the excitation-contraction mechanism of the heart. We found that cocaine and
MDMA could significantly increase intracellular Ca in cultured cardiac myocytes. For
MDMA, the minimal concentration and time required to induce this response was
1X10"3 M at 2 min, and for cocaine, a minimum of 1X10"4 M at 2 min was sufficient.
Again, these findings suggest that under our experimental conditions, cocaine is more
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potent than MDMA in elevating intracellular Ca2+ and that these drugs may alter
intracellular signaling, gene expression, and myocardial rhythmicity and contractility
due to the important role of Ca2+ in these processes.
9+

Since intracellular Ca was significantly elevated upon exposure to cocaine, we
9+

were interested in observing the effects of antioxidant and Ca

channel blocking pre-

9+

treatment on cocaine induced intracellular Ca elevation in cultured cardiac myocytes.
Pre-treatment with 1 mM NAC significantly attenuated the intracellular Ca2+ elevation
normally induced by 1X10"4 M and 1X10"3 M cocaine, but not by 1X10"2M cocaine. We
also found that pre-treatment with either 10 uM verapamil or 10 uM nifedipine
significantly attenuated the intracellular Ca2+ elevation normally induced by 1X10"4 M
9+

cocaine. Verapamil also significantly attenuated the intracellular Ca

elevation normally

induced by 1X10"3M cocaine, although this effect was short-lived.
It is evident that Ca

channel blockers offer significant but limited protection

against intracellular Ca2+ overload induced by cocaine. This finding suggests that
cocaine may mediate some of its effects via altering intracellular Ca2+ signaling and that
the extracellular space is at least one source of this extra Ca2+. Since free-radical
9+

quenching appears to be more effective at higher concentrations of cocaine than Ca
blockade alone, the other source must come from some internal store that sequesters
9-1-

Ca from being free in the cytosol, such as the mitochondria or the sarcoplasmic
reticulum. Because of the destructive nature of free-radicals on biological
macromolecules, it may be possible to physically compromise these membrane bound
internal reservoirs in the absence of sufficient antioxidant protection and cause leakage
of free Ca2+ into the cytosol. The protective property of NAC to help guard against
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abnormal intracellular Ca

elevation has been recently described in lung epithelial

cells.137
Since N F - K B was activated by certain concentrations of cocaine, and

NF-KB

activity enhances the transcription of certain genes, we decided to study the effects of
this drug on modulating genes associated with cardiovascular disease and toxicity. To
determine the effects of cocaine on gene expression profiles, we analyzed gene arrays
with probes made from total mRNA isolated from cocaine treated cultured cardiac
myocytes and rabbit ventricular myocardium. A number of genes associated with
cardiovascular disease were activated by cocaine. It was not feasible to verify the
activation of all genes with a signal ratio of 2.0 or above, therefore only a few genes on
each array were confirmed via RT-PCR. Of particular interest were the genes associated
with ischemia, remodeling, and heart failure, including atrial natriuretic peptide (ANP),
C-reactive protein (CRP), and brain natriuretic peptide (BNP).138"140 Elevated TNFa, an
NF-KB

dependent cytokine, has been linked to apoptosis, inflammation, hypertrophy,

and heart failure.55 The increased transcription of peroxisome proliferator activated
receptor-gamma (PPARy) may be compensatory in response to the oxidative stress
induced by cocaine.141 Activation of the KCNA5 gene could instigate some of the
cardiac arrhythmias seen in chronic cocaine users, due to the important role of voltagegated potassium channels during the repolarization phase of the cardiac action
potential.142 The rapidity of the response in the rabbit heart, with significant increases in
expression within 30 min is not unheard of in other systems.143'144 Increases in Ca2+ and
mitochondrial depolarization are known to be capable of instigating these changes
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during ischemia and heart failure, therefore similar increases caused by cocaine exposure
may also have that potential.
Cocaine mediated activation of many of these genes are consistent with the
clinical profile reported by Missouris et al. and suggests that cocaine may set into motion
transcriptional activity that, if maintained sufficiently, could predispose the individual to
chronic cardiovascular dysfunction.145 Activation of genes in our acute preparations
could contribute to cocaine-induced cardiac toxicity if these changes in gene
transcription are maintained and manifested as changes in cardiac protein expression.
For example, several gene products that could be traced to hypertrophy include increases
in both the [3-adrenergic receptor and angiotensinogen genes. The latter was of specific
interest to us since we previously reported that cocaine increased plasma renin activity
(PRA).18 Angiotensinogen is a precursor for the production of angiotensin II, a strong
vasoconstrictor known to lead to hypertension and cardiac hypertrophy.146'147
Genetic microarry was also used to determine if MDMA could alter gene
transcription profiles in cultured cardiac myocytes. MDMA increased the transcription
of the Cox-2 gene. This gene encodes for an enzyme known to be localized within
regions of myocardial inflammation and fibrotic scar formation, especially in patients
with congestive heart failure.

The upregulation of the MCP-1 and MlP-lb genes

suggests that these chemotactic proteins may promote leukocyte migration to the
myocardium.148,149 The adhesion molecule gene VCAM-1 was strongly upregulated,
displaying a 12-fold increase over control. VCAM-1 may be involved with leukocyte
binding and infiltration into the myocardium.110 This particular gene is specifically
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regulated by N F - K B , corroborating the increased activity of N F - K B observed in our
genetic reporter studies.
The activity of two genes associated with myocardial remodeling and hypertrophy
were also affected by MDMA. Gelatinase A, which encodes for a matrix degrading
enzyme, and its inhibitor Timp were downregulated.150 This suggests that MDMA may
not alter the extracellular matrix. However, the increased transcription of growth
promoting genes such as cyclin Dl, cyclin G, and PCNA suggests that MDMA may be
pro-hypertrophic.151"154 The ability of MDMA to activate growth related genes may act
in synergy with its systemic ability to enhance the release of norepinephrine, another
stimulator of hypertrophic growth in the chronically affected myocardium.117
Several other key genes were activated in the presence of MDMA including heatshock proteins aB-crystallin (cryab), mortalin-2 (PBP74), HSP25, and HSP60. These
pro-survival genes are normally induced by chemical, hyperosmotic, and ischemic
insults.155"158 In addition, the upregulation of DNA-repair factors Gadd45 and RAD23A
suggests that MDMA may also have genotoxic properties.159'160 The activation of these
genes by MDMA suggests that the cells are stressed by the drug and that a compensatory
response is initiated to counteract exposure and promote survival. Furthermore, MDMA
appeared to downregulate the pro-apoptotic genes caspase-1, caspase-8, FasL, and p53
suggesting that under our experimental conditions, the adverse effects associated with
MDMA may not be caused by activation of apoptosis.161"165
Genetic arrays provide the advantage of observing the activity of several genes
simultaneously at the level of transcription. However, changes in mRNA transcript
levels may not be finally manifested as changes in protein expression that significantly
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influence a particular pathology. One important limitation is that post-transcriptional
events may also influence the ultimate expression of a gene in question and this cannot
be determined with the present methodology. We therefore turned to antibody based
methods such as immunohistochemistry and Western blotting in an attempt to measure
the expression of select genes at the protein level. However, for both cocaine and
MDMA, we were unable to observe any significant differences between treatment
groups in either rabbit heart tissue or H9c2 cells. We are not certain why these assays did
not reveal any useful information. It is possible that, at the protein level, the selected
genes are simply not affected by our experimental treatments. Also, technical difficulties
remain a possibility, even though in some instances a strong positive control signal was
obtained.
In our functional studies of the intact rabbit heart, cocaine caused the appearance
of several acute abnormalities, including a significantly decreased heart rate, decreased
inotropy, decreased lusitropy, and increased duration of relaxation. The cocaine
mediated intracellular Ca elevation and increased ROS generation that we observed in
cultured cardiac myocytes could help explain the impairment of ventricular relaxation
and reduced heart rate. Other investigators have shown that cocaine increased oxidative
stress in the myocardium of rats before cardiac dysfunction occurred and that the left
ventricular dysfunction was prevented by antioxidants.166 Another likely contributor to
the decline in heart rate and left ventricular inotropy could be the anesthetic property of
cocaine and its ability to block sodium channel conductance, thereby slowing conduction
velocity through the myocardium. In anesthetized animals, this property has been shown
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to have an overriding effect on the otherwise positive inotropic actions normally
attributed to cocaine.167
MDMA also caused acute functional abnormalities of the left ventricle. Compared
to placebo, MDMA alone caused significant increases in heart rate, end diastolic
pressure, and minimum diastolic pressure. MDMA also caused significant decreases in
lusitropy and duration of relaxation. Interestingly, the effect on inotropy was mixed with
a significant decrease at the 1 min mark followed by a significant increase at the 5 min
mark. Due to the early onset of these cardiovascular responses, and the fact that MDMA
induced N F - K B activation in our cultured cardiac myocytes was not observed at or
before the 3 h time point, these responses may not be the result of interaction with the
myocardial

NF-KB

pathway. Two possibilities may explain these results. The injected
9+

MDMA may have directly and rapidly affected Ca homeostasis in peripheral blood
vessels and led to the slight increase in systolic and diastolic pressures. It is also possible
that MDMA may have stimulated systemic sympathetic activity by causing a net
increase in epinephrine and norepinephrine release from the adrenal medulla and
peripheral nerve endings. This idea is supported by the fact that there was a rapid and
significant increase in heart rate during all time periods tested after MDMA injection.
MDMA caused significant intracellular Ca elevation in cultured H9c2 cells
within a few minutes after administration. Elevated Ca2+ levels may affect intracellular
signaling pathways leading to diverse pathological responses including fibrosis and
hypertrophy. Disruptions in calcium homeostasis may also alter myocardial excitability
and contractility, which may induce ventricular arrhythmia and other more immediate
functional abnormalities such as those observed in the present study. An increase in

heart rate along with a decrease in the duration of the cardiac cycle suggests that filling
and ejection of blood in the heart exposed to MDMA may be acutely compromised.
Although we exposed the H9c2 heart cells to MDMA acutely and measured ROS
generation 5 min later, the half-life of MDMA has been reported to be approximately
8 h.66 In addition, there is evidence that MDMA metabolites adversely affect cardiac
myocyte redox balance.84 MDMA is metabolized into a variety of other compounds all
of which may have biologic activity and thus may prolong the exposure of the
myocardium to the deleterious effects of the drug such as ROS generation. In vivo and
in vitro studies provide evidence supporting the role of oxidative stress in cardiovascular
conditions (ex. ischemia-reperfusion injury, hypertension, and catecholamine-induced
cardiomyopathy) that ultimately lead to cardiovascular dysfunction.168'169
Significant

NF-KB

activity was absent in the myocardial tissue samples from our

functional experiments. Since the animals were exposed to MDMA for 15 min prior to
euthanasia, this lack of N F - K B activity is in agreement with our cell culture findings at
the same time point. Therefore, it is unlikely that any functional abnormalities induced
by acute MDMA exposure are due to the activation of N F - K B within the myocardium
and the consequent expression of downstream dependent genes. However, it is possible
that other tissues, such as the vasculature or sympathetic peripheral nerve endings may
be responsive to this drug within the tested timeframe and may contribute to the
abnormal functional findings in the left ventricle by increasing peripheral resistance or
prolonging catecholaminergic stimulation of the heart. Another possibility that may
explain the rapid effects of MDMA on ventricular function involves MDMA induced
ROS generation and abnormal intracellular Ca2+ elevation. These events may present a
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more immediate threat to normal heart function since they were precipitated quite
rapidly in our cultured cardiac myocytes after drug exposure.
Since MDMA activates N F - K B , we predicted that downstream dependent genes
such as inducible nitric oxide synthase (iNOS) would be upregulated as a result of
MDMA exposure. iNOS is a cardioprotective enzyme closely associated with
compensatory actions in the heart during ischemic preconditioning and inflammatory
cytokine exposure.170'171 It is possible that MDMA stresses the heart and causes the
myocardium to respond in an adaptive manner by increasing the synthesis of this
enzyme. In the current study, we performed an independent series of experiments in
which we again exposed H9c2 heart cells in culture to 2.0 uM and 1.0 mM
concentrations of MDMA. However, we did not observe a significant change in the
expression of iNOS at the protein level.
Regardless of the exact source of nitric oxide, the importance of an intact nitric
oxide response system is readily apparent in our functional experiments. L-NAME is a
well characterized non-specific inhibitor of the major NOS isoforms.172'173 In the rat, this
compound induces a dose-dependent increase in heart rate and mean arterial pressure.172
L-NAME also decreases blood flow by increasing vasoconstriction in several vascular
beds including those associated with the kidneys, mesenteries, and hindquarters.174
In our experiments, injection of L-NAME alone caused a significantly decreased
heart rate, but increased left ventricular systolic and diastolic pressures, Vi relaxation,
and duration of relaxation. In contrast, when MDMA was given alone, heart rate
increased and the duration of relaxation decreased. These results are consistent with
what was expected since the duration of the cardiac cycle is inversely proportional to the
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heart rate. In the presence of L-NAME, MDMA decreased heart rate and increased the
duration of the cardiac cycle. These results suggest that one mechanism used by MDMA
to alter heart function is via the nitric oxide synthase pathway. Nitric oxide has been
shown to play a role in the modulation of sympathetic nerve activity and baroreflex
sensitivity.175 For instance, if MDMA and L-NAME are both sympathomimetic
synergists, then the increased systolic pressure induced by L-NAME may be enhanced
by the addition of MDMA. The consequent decrease in heart rate may be exclusively
due to the effects of L-NAME or the compensatory baroreceptor reflexes of the intact
cardiovascular system responding to the elevations in pressure. It is therefore not
possible, in this model, to separate the reflex component of the response to these drugs.
These findings have important implications for users of MDMA with a compromised
vascular endothelium, as seen in the atherosclerotic vasculature. Endothelial cells are an
important source of nitric oxide. Therefore, users of MDMA with extensive
atherosclerotic lesions may be at increased risk for the development of acute heart
failure.
A myriad of pathophysiological events can be triggered by cocaine or MDMA
administration. Many of these events, such as ischemia-reperfusion of the myocardium,
prolonged catecholaminergic stimulation, and rhabdomyolysis of skeletal muscles, are
well described and can induce ROS generation, intracellular Ca elevation, and
myocardial dysfunction secondary to administration of the drugs themselves. On the
other hand, information concerning the direct/primary effects of cocaine and MDMA on
the myocardium is relatively scarce. Given the high potential for cocaine and ecstasy
abuse, it is important to elucidate mechanisms of pathology in order to effectively

99
identify possible treatment strategies. The current study significantly adds to our
understanding about the effects of cocaine and MDMA on the heart, however, full
characterization of these drugs remains incomplete.
Based on what we have observed, it would be prudent to perform additional
experiments that will complement and extend our understanding about cocaine, MDMA,
and any potential prophylactic agents. For example, although we were able to observe
the beneficial effects of antioxidant pre-treatment in several of our experiments with
cocaine, it remains to be seen if the same type of pre-treatment would be just as effective
in the case of MDMA. Moreover, since the gold-standard in any efficacy study involving
the heart is the measurement of impact on normal function, it would be very interesting
to see if these pre-treatments can help rectify any of the drug induced functional deficits
observed in our in vivo model. In addition, experiments involving clinically relevant
concentrations, patterns of administration, and durations will add to our understanding of
possible long-term sequelae that cocaine and MDMA may cause, as it is likely that these
drugs will prove to be increasingly detrimental to the heart in chronic abusers.
In conclusion, the current findings support our initial hypothesis that cocaine and
MDMA can significantly disrupt cellular homeostasis and normal heart function. At
certain concentrations and time points, both drugs activate N F - K B , increase ROS
generation, elevate intracellular Ca2+, modulate the transcription of certain genes, and
disrupt the normal function of the intact left ventricle. In the case of cocaine, antioxidant
and calcium blocking pre-treatment may be of some benefit as prophylactic measures to
help attenuate myocardial toxicity. Since MDMA alters some of same homeostatic
parameters as cocaine, albeit with less potency, it is possible that a similar pre-treatment
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regime may be beneficial with this drug as well. It is likely that additional mechanisms
and commonalities will reveal themselves upon further research as we gain more insight
into the nature of these important drugs of abuse.
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APPENDIX B

MOUSE CARDIOVASCULAR DISEASE BIOMARKERS ARRAY GENES
Position

Gene name

APOF

2
3
4
5
6
7
8
9
10
11
12
13
14

ANF
Apoal
Apoa2
Apoa4
Apoa5
Apob
Apocl
Apoc2
Apoc3
Apoc4
Apod
APOE
Apoh

15
16
17
18
19
20
21
22
23
24
25
26

Scya2
Cmkbr2/MIP-la
Ckm
Crlfl
Crp
Ctfl
Ednl
Edn2
Edn3
TF
Fga
Fgb

27

FGG

28
29
30
31

HMOX1
ICAM-1
IFNr
IL-10

Description
Mus musculus, Similar to apolipoprotein
F, clone MGC: 19128 IMAGE:4211838,
mRNA, complete cds
ESTs, Highly similar to ANFMOUSE
Atrial natriuretic factor precursor (ANF)
(Atrial natriuretic peptide) (ANP)
(Prepronatriodilatin) [M.musculus]
Apolipoprotein A-I
Apolipoprotein A-II
Apolipoprotein A-IV
Apolipoprotein A-V
Apolipoprotein B
Apolipoprotein C-I
Apolipoprotein C-II
Apolipoprotein C-III
Apolipoprotein C-IV
Apolipoprotein D
Apolipoprotein E
Apolipoprotein H
Mus musculus Chemokine (C-C motif)
ligand 2
Chemokine (C-C) receptor 2
Creatine kinase, muscle
Cytokine receptor-like factor 1
C-reactive protein, petaxin related
Cardiotrophin 1
Endothelin 1
Endothelin 2
Endothelin 3
Coagulation factor III
Fibrinogen, alpha polypeptide
Fibrinogen, B beta polypeptide
Mus musculus fibrinogen gamma-chain
mRNA, partial cds.
Mus musculus heme oxygenase
(decycling) 1
Intercellular adhesion molecule
Interferon gamma
Interleukin 10
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Position
32
33
34
35

Gene name
IL-18
IL-lb
IL1RN
IL-6

36
37
38
39
40

Gpl30
LFAlb/Cd49b
Cd41b
Cd49c
VLA-4

41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57

Integrin a5
Integrin a6
Integrin a7
Integrin a8
Itga9
Itgae
LFAla/CDllA
Cdllb
Cd51
Cdllc
CD29
Cdl8
CD61
Integrin b4
Integrin b5
Integrin b6
Integrin b7

58
59
60

TNFb
LT-b
Mb

61
62
63
64

Clg/Mmpl
Gelatinase A
Gelatinase B
Mrpll5

65

NFkBl

66

iNOS

Description
Interleukin 18
Interleukin 1-beta (IL-1-beta) mRNA
Interleukin 1 receptor antagonist
Interleukin 6
Mus musculus interleukin 6 signal
transducer (I16st)
Integrin alpha 2
Mus musculus integrin alpha 2b
Mus musculus integrin alpha 3
Integrin alpha 4
Integrin alpha 5 (fibronectin receptor
alpha)
Mus musculus integrin alpha 6
Mus musculus integrin alpha 7
Integrin alpha 8
Integrin alpha 9
Integrin, alpha E, epithelial-associated
Integrin alpha L
Mus musculus integrin alpha M
Mus musculus integrin alpha V
Mus musculus integrin alpha X
Integrin beta 1 (fibronectin receptor beta)
Mus musculus integrin beta 2
Mus musculus integrin beta 3
Mouse integrin beta 4 subunit
Mus musculus integrin beta 5
Mus musculus integrin beta 6
Mus musculus integrin beta 7
Mouse tumor necrosis factor-beta mRNA
(Lymphotoxin A)
Mus musculus lymphotoxin B
Myoglobin
Mus musculus matrix
metalloproteinase 13
Mus musculus matrix metalloproteinase 2
Mus musculus matrix metalloproteinase 9
Mitochondrial ribosomal protein LI5
Nuclear factor of kappa light chain gene
enhancer in B-cells 1, pi05
Nitric oxide synthase 2, inducible,
macrophage
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Position
67

Gene name
BNP

68
69

LOX-1
Pappa

70

PEC AMI

71

Pla2g7

72
73

tPA
PLAU

74

PLAUR

75
76
77

Pparg
Saal
E-selectin

78
79
80
81

Selel
L-selectin
P-selectin
Psgll

82
83
84
85

PAI-1
Thbd
Timp
TNFa

86

TNFR2

87

TNFR1

88

Cd40

89

Fas

90

CD40L

91

FasL

Description
Natriuretic peptide precursor type B
Oxidized low density lipoprotein
(lectin-like) receptor 1
Pregnancy-associated plasma protein A
Mus musculus platelet/endothelial cell
adhesion molecule
Phospholipase A2, group VII (plateletactivating factor acetylhydrolase, plasma)
Mus musculus plasminogen activator,
tissue
Plasminogen activator, urokinase
M.musculus muPAR2 mRNA (Urokinase
plasminogen activator receptor)
Peroxisome proliferator activated receptor
gamma
Serum amyloid A 1
Selectin, endothelial cell
M.musculus mRNA for E-selectin
ligand-1
Selectin, lymphocyte
Selectin, platelet
Selectin, platelet (p-selectin) ligand
Mouse plasminogen activator inhibitor,
Serine proteinase inhibitor
Thrombomodulin
Tissue inhibitor of metalloproteinase 1
Mus musculus tumor necrosis factor
Tumor necrosis factor receptor
superfamily, member la
Tumor necrosis factor receptor
superfamily, member lb
Tumor necrosis factor receptor
superfamily, member 5
Tumor necrosis factor receptor
superfamily, member 6
Tumor necrosis factor (ligand)
superfamily, member 5
Tumor necrosis factor (ligand)
superfamily, member 6; Fas ligand
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Position

Gene name

92
93
94
95
96
97
98
99
100
101
102

Tnnc
Tnni3
Tnnt2
VCAM-1
Vwf
pUC18
pUC18
pUC18
0
0
0

103

GAPDH

104
105
106
107
108

GAPDH
CyclophlinA
CyclophlinA
CyclophlinA
CyclophlinA

109

RPL13A

110
111
112

RPL13A
Beta-actin
Beta-actin

Description
M.musculus slow/cardiac troponin C
(cTnC) mRNA, complete cds.
Troponin I, cardiac
Troponin T2, cardiac
Vascular cell adhesion molecule 1
Von Willebrand factor homolog
PUC18PlasmidDNA
PUC18PlasmidDNA
PUC18PlasmidDNA
Blank
Blank
Blank
Glyceraldehyde-3 -phosphate
dehydrogenase
Glyceraldehyde-3 -phosphate
dehydrogenase
Mus musculus peptidylprolyl isomerase A
Mus musculus peptidylprolyl isomerase A
Mus musculus peptidylprolyl isomerase A
Mus musculus peptidylprolyl isomerase A
Mus musculus ribosomal protein LI3a
(23 Kda highly basic protein)
Mus musculus ribosomal protein LI3a
(23 Kda highly basic protein)
Cytoplasmic beta-actin
Cytoplasmic beta-actin

APPENDIX C

MOUSE cAMP/Caz+ SIGNALING PATHWAY FINDER ARRAY GENES
(Ca2 'ARRAY)
Position
1
2

Gene name
Aanat
Adrbl

3
4
5
6

ADRB2
Angiotensinogen
AHR
Amdl

7

ANF

8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24

Arc
Amphiregulin
ATF-3
Bcl-2
BDNF
BRCA1
Clqrf-pending
Cables
Calbl
Calb2
Calb3
CALCRL
Calmodulin 1
Calr
Cyclin Al
CyclinDl
Cdk5

25
26

pl5INK4b
Cga

27
28

Chromogranin A
Cnnl

29
30

CREB
CREM-1

Description
ArylalkylamineN-acetyltransferase
Adrenergic receptor, beta 1
Mus musculus highly similar to beta-2
adrenergic receptor (Adrb2)
Mus musculus angiotensinogen
Aryl-hydrocarbon receptor
S-adenosylmethionine decarboxylase 1
ESTs, Highly similar to ANF MOUSE
ATRIAL NATRIURETIC FACTOR
PREC
Activity regulated cytoskeletal-associated
protein
Mus musculus amphiregulin
Activating transcription factor 3
B-cell leukemia/lymphoma 2
Brain-derived neurotrophic factor
Breast cancer 1
Clq related factor
Cdk5 and Abl enzyme substrate
Calbindin-28K
Calbindin 2
Calbindin-D9K
Calcitonin receptor-like
Calmodulin 1
Calreticulin
Mus musculus cyclin Al (Ccnal)
Cyclin Dl(Ccndl)
Cyclin-dependent kinase 5
Cyclin-dependent kinase inhibitor
pl5INK4b (inhibits CDK4)
Glycoprotein hormones, alpha subunit
Mus musculus chromogranin A
(parathyroid secretory protein 1)
(precursor for vasostatin)
Calponin 1
M.musculus mRNA for transcription
factor/DNA binding protein
cAMP responsive element modulator
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Position
31
32
33

Gene name
Crh
Cyr61
Dbh

34
35
36
37
38

GADD153
Egr-1
Krox-20
Eno2
FGF6

39
40
41
42

c-fos
GOS3
Follistatin
Gcg

43
44
45
46
47
48
49
50

Gem
HK2
Hspa4
Grp78
IL-2
IL-6
INHBA
Jun-B

51

Jundl

52
53

KCNA5
Ldhl

54

Maf

55

MIF

56
57
58

NCAM
Nfl
iNOS

59

Neuropeptide Y

Description
Corticotropin releasing hormone
Cysteine rich protein 61
Dopamine beta hydroxylase
Mus musculus DNA-damage inducible
transcript 3 (Ddit3)
Mouse Egr-1 (Early growth response 1)
Early growth response 2
Enolase 2, gamma neuronal
Fibroblast growth factor 6
Mouse c-fos oncogene (FBJ osteosarcoma
oncogene)
FBJ osteosarcoma oncogene B
Follistatin
Glucagon
GTP binding protein (gene overexpressed
in skeletal muscle)
Mus musculus hexokinase 2 mRNA
heat shock 70 kDa protein 4
Grp78 (78 KD glucose regulated protein)
Mouse interleukin-2
Interleukin 6
Inhibin beta-A
Mus musculus Jun-B oncogene
Mus musculus Jun proto-oncogene related
gene dl
Potassium voltage gated channel, shaker
related subfamily, member 5
Lactate dehydrogenase 1, A chain
Highly similar to MAF2 MOUSE
TRANSCRIPTION FACTOR MAF2
[M. musculus]
Mus musculus migration inhibitory factor
(1 OK protein)
Mouse mRNA for neural cell adhesion
molecule
neurofibromatosis 1
Inducible nitric oxide synthase 2
Mus musculus preproneuropeptide Y
(0710005 A05Rik)
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Position

Gene name

60
61
62
63
64
65
66
67

Nr4a2
Ode
Pck2-Rik
PCNA
Pcx
Enkephalin
Perl
Pitl

68
69
70

tPA
Plf
Pin

71
72

Noxa
Pou2afl

73

Ppp2ca

74
75

Prkarla
prolactin

76

Cox-2

77
78

DUS1
Rb

79

Calgranulin A

80
81
82

Calgranulin B
Scg2
Sgk

83
84
85

s.Slcl8al
Smst
SSTR2

86

SOD2

Description
Nuclear receptor subfamily 4, group A,
member 2
Ornithine decarboxylase, structural
RIKEN cDNA 9130022B02 gene
Proliferating cell nuclear antigen
Pyruvate decarboxylase
Mouse Preproenkephalin 1
period homolog 1 (Drosophila)
Pituitary specific transcription factor 1
Mus musculus plasminogen activator,
tissue (Plat),
Mus musculus proliferin
Phospholamban
Noxa protein (Phorbol-12-myristate-13acetate-induced protein 1)
POU domain, class 2, associating factor 1
Protein phosphatase 2a, catalytic subunit,
alpha isoform
Protein kinase, cAMP dependent
regulatory, type I, alpha
Mouse mRNA for prolactin
Mus musculus prostaglandinendoperoxide synthase 2 (Ptgs2)
Mus musculus protein tyrosine
phosphatase, non-receptor type 16
Retinoblastoma protein
SI00 calcium binding protein A8
(calgranulin A)
SI00 calcium binding protein A9
(calgranulin B)
Secretogranin II
Serum/glucocorticoid regulated kinase
Similar to solute carrier family 18
(vesicular monoamine), member 1, clone
MGC:28683 IMAGE:4239930,
Somatostatin
Somatostatin receptor 2
Mus musculus superoxide dismutase 2,
mitochondrial (Sod2),
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Position

Gene name

87

SRF

88
89
90
91
92
93
94
95
96
97
98
99
100
101
102

APRF
substance P
receptor
Tcra
TGFb3
Th
THBS1
TNFa
Vcl
Vip
pUC18
pUC18
pUC18
0
0
0

103

GAPDH

104
105
106
107
108

GAPDH
cyclophlinA
cyclophlinA
cyclophlinA
cyclophlinA

109

RPL13A

110
111
112

RPL13A
beta-actin
beta-actin

Description
Serum response factor (c-fos serum
response element-binding transcription
factor)
signal transducer and activator of
transcription 3
Mus musculus tachykinin receptor 1
T-cell receptor alpha chain
Transforming growth factor, beta 3
Tyrosine hydroxylase
Mouse thrombospondin 1 mRNA
Mus musculus tumor necrosis factor
Vinculin
Vasoactive intestinal polypeptide
PUC18PlasmidDNA
PUC18PlasmidDNA
PUC18PlasmidDNA
Blank
Blank
Blank
Glyceraldehyde-3 -phosphate
dehydrogenase
Glyceraldehyde-3 -phosphate
dehydrogenase
Mus musculus peptidylprolyl isomerase A
Mus musculus peptidylprolyl isomerase A
Mus musculus peptidylprolyl isomerase A
Mus musculus peptidylprolyl isomerase A
Mus musculus ribosomal protein LI3a
(Rpll3a)(23 Kda highly basic protein)
Mus musculus ribosomal protein LI3a
(Rpll3a)(23 Kda highly basic protein)
Cytoplasmic beta-actin
Cytoplasmic beta-actin
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Position
1

Gene name
annexin A5

2
3
4
5
6
7
8
9
10
11
12

ATM
bax
bcl-x
bcl-w
caspase-1
caspase-8
cyclin C
cyclin Dl
cyclin G
p21Wafl (p21cii
cryab (a-Crystall
B)

13

GM-CSF

14

Cyplal

15

Cypla2

16
17

Cyplbl
Cyp2a5

18

Cyp2bl0

19
20
21
22
23
24
25

Cyp2b9
Cyp2c29
Cyp3al 1
Cyp4al0
Cyp4al4
Cyp7al
Cyp7bl

26

GADD153

27
28
29

Hsj2
E2F-1
egr-1

Description
Mus musculus annexin A5 (Anxa5),
Ataxia telangiectasia mutated homolog
(human)
Bcl2-associated X protein
Bcl2-like
Bcl2-like 2
Interleukin-1 beta convertase (IL-lbc)
Caspase 8
Cyclin C
Cyclin Dl
Cyclin G
Cyclin-dependent kinase inhibitor p21 Wafl
Alpha crystallin B
Colony stimulating factor, granulocyte
macrophage
Cytochrome P450, lal, aromatic compound
inducible
Cytochrome P450, la2, aromatic compound
inducible
Cytochrome P450, lbl, benz[a]anthracene
inducible
cytochrome P450, 2a5
musculus cytochrome P450, 2b 10,
phenobarbitol inducible, type b (Cyp2bl0)
Cytochrome P450, 2b9, phenobarbitol
inducible, type a
cytochrome P450, 2c29
Cytochrome P450, steroid inducible 3a 11
cytochrome P450, 4a 10
cytochrome P450, 4a 14
cytochrome P450, 7a 1
Cytochrome P450, 7b 1
Mus musculus DNA-damage inducible
transcript 3
DnaJ (Hsp40) homolog, subfamily A,
member 1
E2F transcription factor 1
Early growth response 1
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Position
30

Gene name
Ephx2

31

ERCC1

32

XPD

33

XPF

34

XPG

35

FMOl

36

FM04

37
38

FM05
Gadd45

39
40
41
42
43
44

GADD45 b
GPX1
GPX2
GSR
MGST1
Gstm3

45

HMOX1

46

HMOX2

47
48

hsfl (tcf5)
Hspl05

49
50
51
52
53

hsp25 (hspbl)
Hsp60
hsp68
Hspall
Hspa4

Description
Epoxide hydrolase 2, cytoplasmic
Excision repair cross-complementing
rodent repair deficiency, complementation
group 1
Excision repair cross-complementing
rodent repair deficiency, complementation
group 2
Excision repair cross-complementing
rodent repair deficiency, complementation
group 4
Excision repair cross-complementing
rodent repair deficiency,complementation
group 5
Mus musculus flavin containing
monooxygenase 1 (Fmol),
Mus musculus flavin-containing
monooxygenase 4
Mus musculus flavin containing
monooxygenase 5 (Fmo5),
DNA-damage inducible transcript 1
Growth arrest and DNA-damage inducible
45beta
Mus musculus glutathione peroxidase 1
Mus musculus glutathione peroxidase 2
Mus musculus glutathione reductase 1
Glutathione S-transferase, mu 1
Glutathione S-transferase, mu 3
Mus musculus heme oxygenase
(decycling) 1
Mus musculus heme oxygenase
(decycling) 2
M.musculus mRNA for heat shock
transcription factor 1
Heat shock protein, 105 kDa
Mus musculus heat shock protein HSP27
(Heat shock protein, 25 kDa)
Heat shock protein, 60 kDa
Heat shock protein, 70 kDa 1
Heat shock 70kD protein 1 -like
Heat shock 70 kDa protein 4
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Position
54
55
56

Gene name
grp78
hsc73
PBP74

57

chaperonin 10

58
59
60

Igfbp6
IL-18
IL-la

61
62
63

IL-lb
IL-6
TNFb

64

Mdm2

65
66
67

MIF
MT1A
Mt2

68
69
70
71

NFkBl
ikBa (Mad3)
iNOS (NOS2)
PCNA

72

NADPH P450

73

Cox-2

74

RAD23A

75

RAD50

76
77
78
79
80

chk2
Scya21a
Scya21b
MIP-2
(SCYA21)
MIP-la(SCYA3L

81

MIP-lb(Scya4)

Description
Grp78 (78 KD glucose regulated protein)
Heat shock 70kD protein 8
Heat shock protein, 74 kDa, A
Heat shock 10 kDa protein 1
(chaperonin 10)
Mus musculus insulin-like growth factor
binding protein 6 (Igfbp6),
Mus musculus interleukin 18 (II18)
Mouse interleukin 1, alpha
Mouse interleukin 1-beta (IL-1-beta)
mRNA
Interleukin 6
Mouse tumor necrosis factor-beta mRNA
Transformed mouse 3T3 cell double
minute 2
Mus musculus migration inhibitory factor
(1 OK protein)
Metallothionein-I activator
Metallothionein 2
Nuclear factor of kappa light chain gene
enhancer in B-cells 1, pi05
Mus musculus I-kappa B alpha chain
Inducible nitric oxide synthase
Proliferating cell nuclear antigen
NADPH-cytochrome P450
oxidoreductase
Mus musculus prostaglandinendoperoxide synthase 2 (Ptgs2)
Mus musculus RAD23a homolog (S.
cerevisiae)
Mus musculus DNA repair protein
RAD50 mRNA
Mus musculus protein kinase Chk2
(Rad5 3-pending)
Small inducible cytokine A21a (serine)
Small inducible cytokine A21b (leucine)
Mus musculus small inducible cytokine
A21c (serine) (Scya21c)
Macrophage inflammatory protein (MIP)
M.musculus MIP-lb gene for macrophage
inflammatory protein lb
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Gene name

82
83
84

IP-lO(ScyblO)
PAI-1
SOD1

85
86
87
88

SOD2
TNFR2
Trail
FasL

89

TRADD

90

p53

91

UGTBr/p

92

UNG

93

XRCC1

94
95
96
97
98
99
100
101
102

XRCC2
XRCC4
Ku80
pUC18
pUC18
pUC18
0
0
0

103

GAPDH

104
105
106
107
108

GAPDH
cyclophlinA
cyclophlinA
cyclophlinA
cyclophlinA

109

RPL13A

Description
Interferon-gamma induced protein CRG-2
precursor (homologous to human IfilO)
Mouse plasminogen activator inhibitor
Cu/Zn superoxide dismutase
Mus musculus superoxide dismutase 2,
mitochondrial
Murine tumor necrosis factor II receptor
TNF-related apoptosis inducing ligand
Fas ligand
ESTs, Weakly similar to tumor necrosis
factor receptor type 1 associated protein
Transformation related protein 53, Tumor
antigene
Mus musculus (A-l) bilirubin/phenol
UDP-glucuronosyltransferase (UGTBr/p)
Human cDNA for uracil-DNA
glycosylase
Mus musculus X-ray repair
complementing defective repair in
Chinese hamster cells 1
Mus musculus X-ray repair
complementing defective repair in
Chinese hamster cells 2
Mus musculus XRCC4
Mus musculus Ku autoantigen
PUC18PlasmidDNA
PUC18PlasmidDNA
PUC18PlasmidDNA
Blank
Blank
Blank
Glyceraldehyde-3 -phosphate
dehydrogenase
Glyceraldehyde-3 -phosphate
dehydrogenase
Mus musculus peptidylprolyl isomerase A
Mus musculus peptidylprolyl isomerase A
Mus musculus peptidylprolyl isomerase A
Mus musculus peptidylprolyl isomerase A
Mus musculus ribosomal protein LI3a
(Rpll3a)(23 Kda highly basic protein)
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Position

Gene name

110
111
112

RPL13A
beta-actin
beta-actin

Description
Mus musculus ribosomal protein LI3a
(Rpl 13a)(23 Kda highly basic protein)
Cytoplasmic beta-actin
Cytoplasmic beta-actin
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